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resumo 
 
 
As doenças conformacionais são caracterizadas pela acumulação de agregados 
proteicos, destabilização da síntese de proteínas e stress proteotóxico devido a 
mutações, desregulação da rede de stress e defeitos na maquinaria de tradução. No 
entanto, os mecanismos subjacentes a estes fenótipos ainda não são totalmente 
compreendidos. Os tRNAs são moléculas essenciais para a tradução e são 
extensamente modificados. Estas modificações são essenciais para a estabilidade do 
tRNA e para o correto emparelhamento codão-anticodão e são catalisadas por 
diferentes classes de enzimas modificadoras de tRNA. Recentemente, algumas dessas 
enzimas, em particular as que catalisam modificações na região do anticodão do tRNA 
foram encontradas desreguladas em várias doenças, nomeadamente cancro, distúrbios 
metabólicos e neurológicos. 
A ligação entre as enzimas modificadoras de tRNA e o stress proteotóxico 
como mecanismo subjacente da doença não se encontra experimentalmente 
demonstrada. Assim, estabelecemos a hipótese de que a desregulação destas enzimas 
- especialmente aquelas que catalisam modificações na posição 34 - afetam a fidelidade 
da tradução, resultando na agregação de proteínas e na ativação da UPR, características 
das doenças acima mencionadas. 
Para testar esta hipótese, implementámos um método fluorescente baseado 
em siRNAs em células HeLa expressando um sistema repórter de agregação 
desenvolvido por nós. Das enzimas testadas, o silenciamento das que pertencem ao 
Elongator Acetyltransferase Complex (ELP) levou à acumulação mais marcante de focos 
fluorescentes nas células, indicando a ocorrência de agregação de proteínas. 
Experiências adicionais demonstraram que a taxa de síntese proteica é afetada, bem 
como a morfologia mitocondrial e alguns mecanismos de controlo de qualidade. 
Este estudo preliminar demonstra pela primeira vez, em células de mamífero 
que existe uma ligação entre as enzimas modificadoras de tRNA e a acumulação de 
agregados proteicos, indicando que estas moléculas podem ser importantes alvos 
terapêuticos nas doenças conformacionais.  
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abstract 
 
Protein conformational diseases are characterized by accumulation of protein 
aggregates, impaired protein synthesis and proteotoxic stress due to mutations, down 
regulation of the stress network and defects in the translation machinery. However, 
the mechanisms underlying these phenotypes are not yet understood. tRNAs are main 
players of the translation machinery and tRNA modifications are essential for efficient 
codon-anticodon recognition influencing translation efficiency. These modifications 
are catalyzed by different classes of tRNA modifying enzymes that have been found 
deregulated in several diseases, namely cancer, metabolic and neurological disorders.
 
 
The connection between tRNA modifying enzymes and proteotoxic stress as 
an underlying mechanism of disease was not experimentally demonstrated. We have 
hypothesized that deregulation of these enzymes  especially those that catalyze 
modifications at position 34  affect translation fidelity, resulting in protein aggregation 
and UPR activation, hallmarks of the above-mentioned diseases. 
To test this hypothesis, we implemented a tRNA modifying enzyme 
fluorescent based siRNA screen in HeLa cells expressing a protein aggregation reporter 
system developed by us. From all the tested enzymes, knockdown of the ones 
belonging to the Elongator Acetyltransferase Complex (ELP) family led to the most 
striking accumulation of fluorescent foci in cells, indicating that protein aggregation 
was occurring. Additional experiments demonstrated that protein synthesis, 
mitochondrial morphology and some quality control mechanisms were also affected.  
This preliminary study demonstrates for the first time in mammalian cells a 
relation between tRNA modifying enzymes deregulation and accumulation of protein 
aggregates, indicating that these enzymes can constitute relevant novel therapeutic 
targets in conformational diseases.  
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1.1 From RNA to protein   
The determination of the iconic three-dimensional structure of the DNA double helix by 
Watson and Crick reversed the understanding of life. This discovery led Crick to formulate the 
central dogma of genetic information that includes how DNA replication occurs, its transcription 
into ribonucleic acid (RNA) and translation into protein (1,2).  
The instructions to build proteins are encoded in the cells’ DNA. As described in the central 
dogma of molecular biology, information from a gene can be used to build a protein in a two-
steps process. The first   transcription   in which the DNA sequence of a gene acts as a 
template for synthesis of an RNA transcript. In eukaryotes, this transcript goes through 
additional processing steps to become a mature messenger RNA (mRNA). In the second – 
translation  the nucleotide sequence of the mature messenger RNA (mRNA) is "decoded" to 
build a polypeptide product (a protein or protein subunit) with a specific sequence of amino 
acids (3). 
In an mRNA, the sequences of three nucleotides (codons) are used to build a polypeptide. 
There are 61 different codons that code for 20-22 amino acids. This means that some amino 
acids are encoded by multiple codons and this is why the genetic code is degenerate. Three 
additional stop-codons, UAA, UAG, and UGA, indicate when a polypeptide is completely formed. 
One codon, AUG, specifies the amino acid methionine and works as a start-signal, 
simultaneously (4).  
This group of codon-amino acid relationships is called the genetic code, as it allows a 
nucleotide sequence to be decoded into a chain of amino acids.  This code is nearly universal. 
With only minor exceptions, a single coding dictionary is used by almost all viruses, prokaryotes, 
archaea, and eukaryotes, as shown in figure 1. The deciphering of the genetic code and the 
demonstration of its universality represented one of the most important discoveries in biology 
(5). 
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During translation, the codons of an mRNA transcript are read sequentially (from 5' to 
3') by special RNA molecules called tRNAs. Each of them recognizes just one or a few codons and 
delivers the corresponding amino acid, which is added to the C-terminus (carboxyl group end) 
of the growing polypeptide. In this way, a chain of amino acids is built, one at a time and the 
sequence of amino acids in the chain reflects the sequence of codons found in the mRNA. Once 
a stop-codon is reached, the polypeptide is complete (6).  
The acuity in information transference is carefully controlled at each step during gene 
expression. The most error-prone steps occur at the ribosome, where an aminoacyltRNA is 
matched with the corresponding codon on the messenger RNA, and an amino acid is paired with 
a tRNA by an enzyme, aminoacyl-tRNA synthetase (ARS). With a few exceptions, errors from the 
aminoacylation reaction cannot be fixed, which almost – with an error rate as shown in the 
figure 2  inevitably leads to the incorporation of the wrong amino acid during protein synthesis 
(7).   
 
Figure 1: Representation of the genetic code and its variations: the amino acids are specified by each 
mRNA codon (constituted by three nucleotides). Multiple codons can code for the same amino acid. 
Differences to the standard genetic code are shown in red for mitochondrial, blue for ciliate and 
Euplotid nuclear code, and orange for the ambiguous yeast nuclear code. Sec and Pyl are shown in 
black. Adapted from: (6). 
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As a consequence, the cells activate mechanisms capable to tolerate certain degree of errors. 
However, if there are other factors that lead to an increase of these errors, the cells are probably 
not able to get rid of the wrong proteins and this can lead to proteotoxic stress – where 
catastrophic loss of accuracy in protein synthesis can occur (8). 
 
 
 
 
 
 
 
. 
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Selection of tRNAs by 
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Figure 2: Translation enables the transfer of information from the messenger RNA into an amino-acid 
sequence at ribosomes, thanks to the amino-acid-specific transfer RNAs (tRNAs). Both steps of this process are 
prone to error (typical rates are shown in red). The inset shows the aminoacylation of tRNA, in which an amino 
acid is paired with a tRNA by the corresponding ARS. Once synthesized, a protein usually becomes functional. 
In some cases, however, misfolding occurs. Most misfolded proteins are degraded by the cell  but if the 
degree of misfolding surpasses the cell capacity to deal with those proteins, some can form insoluble 
aggregates that, can lead to states of proteotoxic stress that are characteristic of conformational disorders, for 
example neurological diseases.  Adapted from: (7). 
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1.1.1 The three stages of the process  
 
The translation process, as a dynamic and continuous process, can be subdivided into 
three major stages: initiation; elongation; and termination of the polypeptide chain and its 
recycling (9).  
Stage 1: Initiation 
The first step in translation is the assembly of the initiation complex, which consists of 
an mRNA, the small (40S) and large (60S) ribosomal subunits, and an initiator tRNA, carrying one 
amino acid in the P-site  specified by the first codon, or start-codon, of an mRNA coding 
sequence. When completely assembled, the initiation complex consists of a ribosome 
sandwiched around an mRNA, with the initiator tRNA bounded to a start-codon. A group of 
proteins called eukaryotic initiation factors (eIFs) (Table 1) help to assemble the initiation 
complex using energy provided by hydrolysis of adenosine triphosphate (ATP) or guanosine 
triphosphate (GTP), an energy storage molecule similar to ATP (10,11).  
Initiation factors eIF1A, eIF3 bind to the 40S ribosomal subunit.  The initiator tRNA 
bearing methionine is bounded by eIF2 (complexed with the GTP), and form a complex with the 
40S subunit and eIF1. The 5' cap of an mRNA is attached to this ribosomal subunit by eIF4E, 
eIF4G  which binds to both eIF4E at the 5´ cap and poly-A binding protein (PABP) at the 3´poly-
A tail - eIF4A, and eIF4B. Then, the ribosome goes downstream in the 3' direction until it reaches 
the start-codon, AUG. This process is known as scanning, and the small subunit may scan 
through hundreds of nucleotides before reaching the start-codon, requiring energy obtained by 
ATP hydrolysis. Once a start-codon has been selected, eIF5 triggers the hydrolysis of guanosine 
triphosphate (GTP) bounded to eIF2  complex to GDP  and other initiation factors. The 60S 
ribosomal subunit joins the 40S complex, enabled by eIF5B and establishes the initial conditions 
for translation (7).  
Stage 2: Elongation 
Elongation occurs when the polypeptide chain gets longer, with the addition of new 
amino acids. In elongation, the ribosome moves along the mRNA in the 5’ to 3’ direction. The 
ribosome has three sites for tRNA binding, namely the P (peptidyl), A (aminoacyl), and E (exit) 
sites. The initiator methionyl-tRNA binds to the P site and the next aminoacyl-tRNA binds to the 
A site, by pairing with the second codon of the mRNA (7).  
The aminoacyl-tRNAs are chaperoned to the ribosome by elongation factors (eEF1α) 
enabling amino acids incorporation, one-by-one, to the C-terminus (carboxyl group end). A 
linear chain of amino acids (polypeptide) with the N and C termini are marked. The N-terminus 
has an exposed amino group. The C-terminus has an exposed carboxyl group. The carboxyl group 
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exposed at the C-terminus of a polypeptide reacts with the amino group of an incoming amino 
acid, forming a peptide bond. This reaction adds the new amino acid to the chain. The carboxyl 
group of the newly added amino acid becomes the new C-terminus of the polypeptide (12).  
During translocation, the ribosome moves one codon over on the mRNA towards the 3' 
end. This shifts the tRNA from the A to the P site and the tRNA from the P to the E site. The 
empty tRNA in the E site leaves the ribosome. When the entire coding sequence of the mRNA 
has been read, a stop-codon will get into the A site of the ribosome, signalling that the 
polypeptide is completely formed and must be released (13). 
Stage 3: Termination and recycling  
Termination is the stage in which translation ends and the completed polypeptide is 
released. It occurs when a stop-codon (UAG, UAA, or UGA) gets into the A site of the ribosome 
and a protein called a release factor (eRF1) binds to it. The binding of the release factor causes 
a water molecule to be added to the end of the polypeptide (in place of an amino acid), breaking 
the bond that connects it to the tRNA in the P site, resulting in a release of the completed 
polypeptide from the ribosome (9).  Finally, the ribosome-recycling occurs, which is 
characterized by the release of ribosomes from the mRNA after termination and splitting of the 
ribosome (10). 
 
Table 1: Some factors and functions associated with the translation process.  Adapted from:(9). 
Factor Known Function in Translation 
eIF1 AUG recognition 
eIF1A (IF1) Scanning/ AUG recognition 
eIF2 (IF2) Met-tRNA binding 
eIF2B Recycles eIF2 (guanine nucleotide exchange factor) 
eIF3 (IF3) Ribosome binding 
eIF4A RNA Helicase 
eIF4B Facilitates eIF4A activity 
eIF4E Cap-binding 
eIF4F Complex of eIF4E, 4G and 4A 
eIF4G Scaffold protein 
eIF5 GAP (GTPase-activator protein) 
eIF5B (IF2) Late stage in initiation, promotes subunit joining 
PABP Binds poly (A) and eIF4G 
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1.2 Transfer RNAs 
 
In 1957, Francis Crick1 proposed the existence of an “adaptor molecule” that could 
covalently bind to the amino acid and also be capable of hydrogen bonding to a nucleotide 
sequence (13). Now, we know that the Crick’s prediction was correct  the transfer RNA (tRNA) 
 serves as the adaptor in protein synthesis, and the ribosome accommodates two tRNA 
molecules at a time, as previously described (14).  
The first nucleic acid to be completely sequenced was the tRNA that binds the amino 
acid alanine (tRNAAla) from yeast. Of great interest was the finding that a number of nucleotides 
are unique to tRNA, each containing a so-called modified base. This pioneering work was 
performed by Holley and co-workers long before the invention of today's rapid sequencing 
techniques. For his work, Holley received the 1968 Nobel Prize in Physiology or Medicine  (15). 
Holley’s sequence analysis led him to propose the two-dimensional cloverleaf model of 
the tRNA molecule. It had been known that tRNA molecules have a characteristic secondary 
structure created by base pairing. He discovered that the linear sequence could be arranged in 
such a way that several stretches of base pairing would be formed. His arrangement, with its 
series of paired stems and unpaired loops, resembled the shape of a three-clover leaf. The loops 
consistently contained modified bases that did not generally form base pairs (16). 
There are 4 arms and 3 loops: the loop closest to the 5' end is called the dihydrouridine 
arm (D arm) because it contains dihydrouridine bases, which are unusual nucleotides common 
only to tRNA. The loop closest to the 3' end is called the T arm, after its sequence of thymine-
pseudouridine-cytosine (pseudouridine is also an unusual base). The loop on the bottom of the 
cloverleaf contains the anticodon, which binds complementarily to the mRNA codon. Because 
anticodons bind with codons in the antiparallel method, they are written from the 5' end to 3' 
end, the inverse of codons (Figure 3). The genetic code relies on the interaction between the 
three bases of the mRNA’s codon triplet (numbered 1, 2, and 3) and the three anticodon bases 
of the cognate aminoacyl-tRNA (numbered 36, 35, and 34 in the anticodon stem loop) (17).  
                                                          
1 In 1955 Crick wrote "On Degenerate Templates and the Adaptor Hypothesis", an unpublished paper which predicts 
the existence of transfer ribonucleic acid (tRNA); In 1957, proposes the "Sequence Hypothesis" and the "Central 
Dogma," path-breaking concepts about how genetic information is encoded in DNA and controls protein synthesis. 
<In National Library of Medicine (NLM)>. https://profiles.nlm.nih.gov/ps/display/About at 22 of July of 2016.   
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Although the standard rules of the Watson-Crick pairing (A/U, U/A, G/C, C/G) strictly 
govern the interaction between base pairs 1/36 and 2/35, the 3/34 base pairing can be 
nonstandard (wobble interaction) (17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Posterior studies on this molecule have allowed the identification of 30  40 different 
tRNA in bacterial cells and around 50 - 100 tRNAs in animals and plant cells. The number of 
tRNAs in most cells is larger than the number of amino acids found in proteins – 20-22   and 
also differs from the number of codons in the genetic code. Consequently, many amino acids 
have more than one tRNA to which they can attach; in addition, many tRNAs can attach to more 
than one codon. As noted previously, most amino acids are encoded by more than one codon, 
requiring some tRNAs to recognize more than one codon (17). 
Immediately after synthesis, the tRNA, like all RNAs, contains the four bases A, G, C and 
U. However, mature tRNAs can contain modified bases – different from the canonical bases 
mentioned above. These modifications are introduced after transcription of the tRNA and the 
most modified bases occur at restricted sites. The first base in the anticodon, the wobble 
position, often contains modified bases that allow the formation of unusual base pairs with the 
third base in the mRNA codon (18).  
HO Amino acid binding site 
Variable 
loop 
5´ 
3´ 
tRNA 
5´ 
Anticodon 
3rd   2nd    1st 
Codon mRNA 
Wobble base 
3´ 
34    35    36 
Figure 3: Illustration of Holley’s two-dimensional model of transfer RNA. Different organisms use distinct 
but convergent strategies to optimize decoding by modifying specific tRNAs, predominantly at position 
34 of the Anticodon Stem-Loop (ASL) (which interacts with the third codon base via non-Watson-Crick 
base pairing or wobble base pairing). Adapted from: (110, 111). 
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Subsequently, maturation of the tRNAs is required, which happens via several steps 
through pre-RNAs or primary tRNAs. In the first step, the transcription of tRNA genes in pre-
tRNA is accomplished by the activity of an enzyme termed RNA polymerase III. Next, the 
sequences – 5' leader and 3' trailer of the pre-tRNA structure – are removed from 
endonucleolytic cleavage catalyzed by RNase P and RNase Z, correspondingly.  Next the 
trinucleotides "CCA" are attached to the 3' termini of tRNAs through CCA-adding enzymes. It is 
noteworthy that modification events occur at this stage, resulting in different non-canonical 
bases at various positions. Lastly, the resulting mature tRNA is aminoacylated by their 
aminoacyl-tRNA synthetases cognates, and participate in the translation process at the 
ribosome (Figure 4) (19,20). Both  pre-mature tRNA and mature tRNA  serve as substrates for 
the production of tRNA fragments (TRFs) a novel class of regulatory non-small RNAs that are 
beyond the scope of this thesis (20).   
 
 
Figure 4: Process of maturation of tRNAs: Once transcribed, tRNAs are sequentially processed at their 5′ 
and 3′ ends to generate a mature tRNA that can be charged with an amino acid. The 5′ leader sequence 
is almost universally cleaved off by the endonuclease RNase P, while multiple mechanisms have been 
reported for tRNA 3′ end processing. In humans, the endonuclease RNase Z cleaves downstream of the 
unpaired discriminator base, releasing the 3′ trailer sequence. Finally, the addition of specific enzymes of 
nucleotide "CCA" at the 3' terminal of tRNA occurs. Adapted from: (19). 
 
In this process of decoding the genetic message, the recognition of the codon or codons 
specifying a given amino acid by a particular tRNA is actually the second step. The first step is 
the attachment of the appropriate amino acid to a tRNA, catalyzed by a specific ARS.  In 1957, 
Paul Zamecnick and Mahlon Hoagland discovered this group of 20 enzymes  (one for each amino 
acid), and they have been related to diseases such as cancer, neuronal disorders, autoimmune 
disorders, among others (21,22).  
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In detail, each ARS charges a specific tRNA molecule with its cognate amino acid via a 
two-step enzymatic reaction. In the first step, the ARS binds the amino acid and ATP molecule 
to form the aminoacyl adenylate (AA-AMP) intermediate, and a pyrophosphate molecule (Ppi) 
is released. In the second step, a tRNA molecule binds the ARS via the anticodon binding domain, 
and the amino acid is transferred to the tRNA. An AMP molecule is then released, followed by 
the charged tRNA and the ARS is free to charge another tRNA molecule (23). 
 
1.2.1 tRNA modifications  
 
Post-transcriptional modification is a critical processing step  catalyzed by tRNA 
modifying enzymes  that results in functional tRNA molecules, allowing folding, stability 
and decoding (24). Over the years, modified nucleosides have been sequenced, and the type 
and location of each one has been identified in GtRNAdb, MODOMICS and RNApathwaysDB 
databases. Different tRNAs are able to suffer different modifications at specific positions. It 
reflects the evolutionary conservation among tRNAs from the three domains of life. Also, 
complex modifications require several enzymes (25). In general, hypomodified tRNAs are 
targeted for degradation since they can have negative consequences for cells, such as reduce 
protein production, to ribosome pausing at cognate codons.  These results suggest that the 
chemical complexity is necessary to maintain the homeostasis of translational process (26).  
 
1.2.2 Types and functions of tRNA modifications 
 
Modified nucleotides are generally characterized by relatively simple chemical 
structures, such as: the addition of one (or sometimes two) methyl groups to various positions 
of the nucleotide bases and or ribose sugars, replacement of oxygen with sulfur (in s2U), 
isomerization or reduction of the uridine base to pseudouridine or dihydrouridine, respectively, 
or addition of other relatively small chemical functional groups (i.e., acetylation and 
threonylation) (27). More specifically, wobble modifications, at the position 34, include uridine 
(U) modifications through incorporation of hydroxyl, methyl, and thiol groups and adenosine (A) 
modifications such as adenosine-to-inosine (A-to-I) editing (28).  Adding cm5U group on uridines 
at the wobble position requires the six-subunit Elongator (ELP) complex. That, in association 
with methyltransferase Alkylation repair homolog 8 (ALKBH8), catalyzes the formation of 5-
methoxycarbonyl-methyluridine (mcm5U) at the wobble position. This substrate can be thiolate 
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by an enzymatic cascade involving Urm1, Uba4, Ctu1, Ncs2 and Ncs6 to yield mcm5s2U (Figure 
5) (28).  
 
 
 
 
 
 
 
 
 
 
 
 
Modifications in the stem–loops are crucial for tRNA structure and stability. The 
pseudouridines modifications can act in sugar conformation of the nucleobases, increasing 
binding affinity and rigidify the tRNA structure; on the other hand, dihydrouridines modifications 
help to maintain the flexibility of the tRNA structure (26). However, modifications in the 
anticodon loop can directly affect the tRNA function in translation and increase the accuracy by 
reading frame maintenance or preventing translational frameshifting (29). Modifications at 
position 34 are generally associated with decoding by increasing the diversity of codon 
recognition through codon–anticodon wobbling. Modification at this site is conserved in 
bacteria and eukaryotes, which has evolved in parallel to the species. Furthermore, post-
transcriptional modifications at base 37, adjacent to the anticodon loop, help to stabilize codon–
anticodon interactions by providing base-stacking interactions (16).  
Figure 5: Chemical modifications associated the enzymes of Elongator Complex, ALKBH8 and others. 
Adapted from: (28).    
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1.2.3 tRNA modifying enzymes and associated diseases  
 
Several studies  in yeast and human homologs  have demonstrated the role played by 
these enzymes in tRNAs and some of those molecules have been associated with diseases 
(Figure 6) (Annexes Table 9):  
The adenosine deaminase, tRNA - specific 3 (ADAT3) catalyzes the deamination 
reaction of adenosines converting them in inosine at the position 34, 37 and 57 of tRNAs (30). A 
single missense mutation in humans (valine128-to-methionine substitution), that results in a 
loss of protein function, was recently reported in individuals affected with intellectual 
disabilities – from mild to profound  and strabismus (31).  
The RNA Methyltransferase Homolog 1 (FTSJ1)  encodes the methyltransferase 
required for mC32 and mG34 modification of tRNAPhen (32);  mutations, such as substitution of 
Guanine655-to-Adenine and  deletion of a guanine nucleotide in exon 2, are associated with 
different phenotypes, namely: Mental retardation X-linked type 44 (MRX44), Mental 
retardation, X-linked 99 and X-linked non-syndromic intellectual disability (32–34).  
Also, allelic variants of Elongator protein 3 homolog (ELP3) have been associated with 
amyotrophic lateral sclerosis (ALS), and their knockdown in zebrafish resulted in motor axonal 
abnormalities (35). Also, the human ELP4 gene has been associated with Rolandic epilepsy, the 
most common type of human epilepsy (36).  
The tRNA modifying enzymes, NOP2/Sun RNA methyltransferase family member 2 
(NSUN2)   and methyltransferase like 1 (METTL1) are mammalian orthologous of yeast Trm4 
and Trm8, which are required for protecting tRNA against rapid tRNA decay. NSUN2 has been 
initially identified as a substrate of AURKB protein kinase in HeLa cells and encodes a 
methyltransferase that catalyzes the methylation of cytosine to 5-methylcytosine (m5C) at 
position 34 of intron-containing tRNALeu (CAA) precursors (37). This also happens at position 48, 
49, and 50 in the variable arm of tRNAGly (GCC) precursor (38). The mentioned modification is 
necessary to stabilize the anticodon-codon pairing and to the accuracy of the mRNA translation. 
In cases of mutations, mental retardation, autosomal recessive 5 (39) and Dubowitz syndrome 
are associated (38).  
The METTL1 catalyzes the formation of N(7)-methylguanine at position 46 (m7G46) and 
has been initially identified as a substrate of PKBα  Akt/protein kinase Bα  in HeLa cells (40). 
In this case, a single nucleotide polymorphism (SNP) is associated and located at the 3' 
untranslated region (3' UTR) of the METTL1 gene and has been implicated in Multiple Sclerosis 
(MS) (41).  Mitochondrial tRNA-specific 2- thiouridylase 1 (MTU1) is a mitochondrial homolog 
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of bacterial MnmA. Its partial inactivation in cultured cells by siRNAs was shown to result in both 
a lack of s2U formation and reduced mitochondrial oxygen consumption.  
Mutated MTU1, acting as a modifier factor, modulates the phenotypic manifestation of 
the deafness-associated with 12S ribosomal RNA mutations (42). Moreover, mutations from 
cells of patients with myoclonus epilepsy associated with ragged-red fibers (MERRF), lacks the 
τm5s2 U modification (43).  Figure 6 contains information collected from various studies that 
associate defects in tRNA modifications and human diseases such as cancer, T2D, neurological 
disorders, and mitochondrial-linked disorders (44).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Schematic representation of the clover leaf tRNA secondary structure with respective 
modifications and tRNA modifying enzymes (in parenthesis) that catalyze them and that have been linked 
to human pathologies – illustration indicated in front of each box. Connecting lines between RNA residues 
indicate base pairing. Asterisks indicate modifications that are only found in mitochondrial tRNAs. Adapted 
from: (44). 
    14 
 
1.2.4 Protein folding and misfolding 
 
Once a polypeptide has been translated, it has to fold into the correct three-dimensional 
shape in order to work correctly. Some polypeptides must also be chemically modified, cleaved 
into smaller pieces, combined with other polypeptides, or shipped to particular organelles (45). 
Proteins all begin their synthesis in the cytosol. Many of them are there permanently, 
but some are transported to other cellular destinations and some are completely synthesized in 
the cytosol. These may be imported into the mitochondrion, peroxisome, chloroplast, and 
nucleus via post-translational transport. Other proteins are co-translationally imported into the 
endoplasmic reticulum. From there, most go to the Golgi apparatus by vesicle transport to the 
cell exterior (for secretion), the plasma membrane, the lysosome, or other parts of the 
endomembrane system (46). 
Most of the signalling proteins used by eukaryotic cells to communicate with their 
environment are assembled in the ER. This transmission and management of information 
through proteins are essential for sustaining cell function (47).  
When proteins are correctly folded and they achieve their native conformation, the 
hydrophobic regions of the polypeptide are confined within the structure in order to maintain 
the lowest possible energy state (48).However, protein misfolding can occur due to mutations 
or environmental factors, that may contribute to expose the hydrophobic domains, promoting 
oligomerization and aggregation of the protein (49). During this process of aggregation, the 
exposed hydrophobic areas interact with other proteins, leading to malfunction of diverse 
cellular pathways (50). Quality control mechanisms (QCM) are activated, attempting to 
neutralize the damaging agent. Molecular chaperones, such as HSP70-family proteins, bind to 
hydrophobic polypeptide structure, blocking their interaction and minimizing aggregation (49). 
The cell also attempts to target the aggregates to degradation, via the proteasomes or 
autophagy. If these attempts fail, as a last resource, the misfolded protein molecules assemble 
through beta sheet-containing domains into amyloid fibrils with cross-beta cores (51), which 
accumulate into large depositories where the hydrophobic areas are less exposed to damaging 
interactions. To sum up, the proteins have three major folding fates inside the cells in order to 
maintain proteostasis (Figure 7) (45).  
Protein aggregation is a hallmark of conformational disorders, namely neurological 
diseases including Alzheimer’s, Parkinson’s or ALS. Despite the fact that in most of these 
diseases the misfolded protein is located in the cytosol or nucleus, paradoxically one main 
consequence is interference with processes in the  endoplasmic reticulum (ER), causing ER stress 
and, in long-term, mitochondrial damage and cell death (52). 
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 Indeed, there is an increasing evidence that this is the main pathway of cytotoxicity 
(53). In a recent study (54) it is referred that the aggregation in the cytoplasm interfered with a 
nucleus-cytoplasmic protein and RNA dislocation.  In contrast, the same proteins did not inhibit 
location when forming inclusions in the nucleus and at/or around the nucleolus. Protein 
aggregation in the cytoplasm, but not in the nucleus, cause the appropriation and dislocation of 
proteins containing disordered and low complexity sequences. Impairment of nucleus-
cytoplasmic dislocation may contribute to the cellular pathology of various aggregate deposition 
diseases (49).  
Figure 7: Protein fates in the Proteostasis Network (PN). The PN integrates chaperone pathways for the 
folding of newly synthesized proteins, the remodeling of misfolded states, and disaggregation with 
protein degradation. 
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1.3 Proteotoxic stress and protein quality control pathways:  
 
Any error in protein folding for physiological or pathological processes may lead to ER 
stress and activates a set of signalling pathways described below (55) (48). The activation of 
these ER transmembrane receptors induces a series of transcription factors that targets an ER 
stress–response element (ERSE) in the promoter region of genes encoding for ER chaperone 
proteins, folding enzymes, and components of the ER-associated degradation (ERAD) process. 
The activation of these genes enhances the cell’s folding capacity and the degradation of 
misfolded and aggregated proteins, allowing the cell to relieve the stress and restore ER 
homeostasis (56)(57) (Figure 25- Annexes). 
 
1.3.1 Chaperones and heat shock response 
 
Molecular chaperones are defined as an ubiquitous family of folding modulators that 
play a central role in the conformational quality control of the proteome by assisting and 
stabilizing  the correct non-covalent assembly of polypeptides (58).  
The chaperone function is associated with stabilization of unfolded proteins, 
translocation across membranes or degradation, and/or to assist in their correct folding and 
assembly.  The large diverse family of molecular chaperones includes (but is not limited to) many 
heat-shock protein families. It is important to note that some heat-shock proteins are in the cell 
at a certain level all the time, even under non-stressed conditions. The heat-shock protein 
families include hsp40, hsp60, hsp70, hsp90, hsp100, and the “small hsps” (59). The numbers in 
the names of these families refer to the size of the corresponding protein, allowing the 
differentiation among them. For example, hsp70 has approximately 70,000 Daltons, a standard 
unit of measuring mass in proteins (37).  
As a part of chaperone family, heat-shock proteins are essential, and the expression of 
some of them drastically increase during the heat-shock response (Table 2). These proteins can 
protect the cell by helping it to survive under conditions that would normally be lethal (59). 
Aggregates resulted for example, from neurodegenerative disease associated-proteins often 
take molecular chaperones, impairing proteostasis (60) (61).  
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Table 2: Families of molecular chaperones.  Adapted from: (62). 
  
Small heat shock proteins 
(HSP25)  
Protect from cellular stress; prevent aggregation in the lens 
(cataract). 
Small heat shock proteins 
(HSP27) 
Inhibition of apoptosis; protection against oxidative stress and 
assist in protein degradation by the proteasome. 
Hsp60 system 
(cpn60,GroEL) ATPase  
Protein folding; prevention of aggregation. 
Hsp70 system (DnaK, 
BiP) ATPase 
Stabilization of extended chains; membrane translocation; 
unfolding; regulation of the heat shock response; targeting 
substrates for degradation. 
 
Hsp90 ATPase Binding, stabilization and maturation of steroid receptors and 
protein kinases; delivery to proteases; buffer for genetic 
variation; regulation of substrate selection and fate; myosin 
assembly. 
 
Hsp100 (Clp) ATPase Thermotolerance; proteolysis; resolubilization of aggregates; 
remodelling; unfolding. 
 
 
1.3.2 Unfolded Protein Response (UPR) 
 
Several studies state that mutations, environmental factors or ageing, may promote 
oligomerization and aggregation of proteins.  Each of these situations can activate the UPR 
response via three ER transmembrane receptors: a) PKR-like ER kinase (PERK); b) Inositol-
requiring enzyme 1 (IRE1); c) activating transcription factor 6 (ATF6) (63) (64) (Figure 9).  
 
a) The Pancreatic Endoplasmic Reticulum-resident Kinase (PERK) Pathway 
 
PERK (also called PKR-related ER-resident kinase) is a serine/threonine kinase and is a 
member of the eIF2 Kinase family. After activation, PERK’s phosphorylates are the eukaryotic 
initiation factors, resulting in translation attenuation of transcripts with a 5´cap. This eIF2α 
phosphorylation reduces the protein load on the ER membranes and attenuates cell growth and 
proliferation. PERK has also been shown to be directly involved in phosphorylation of the nuclear 
factor  erythroid 2-related factor 2 (NRF2)  a transcription factor involved in redox 
metabolism, as for example antioxidant responses (65).  
    18 
 
Phosphorylation of eIF2α allows the translation of Activating Transcription Factor (ATF4) 
mRNA, which encodes a transcription factor controlling the transcription of genes involved in 
autophagy, apoptosis, amino acid metabolism and antioxidant responses (66). 
Studies in humans, investigations using PERK−/− mice and mice (Ser51Ala) with a 
mutation in the phosphorylation site of eIF2α showed a potential relationship between ER stress 
and β-cell function (67) (68). It suggests that lack of PERK leads to severe cell dysfunction and 
diabetes (67). Moreover, activation of heterozygous eIF2α mutant mice on a high-fat diet causes 
distension of the ER lumen in cells, a reduction in islet insulin content and diabetes (69).  Also, 
endoplasmic reticulum (ER) stress is considered a major alteration in obesity, leading to 
suppression of insulin receptor substrate-1 (IRS-1) signaling, mediated by hyper-activation of 
the c-Jun N-terminal kinase (JNK) and subsequent serine phosphorylation (70).  
 
b) The Inositol-Requiring Enzyme 1 (IRE1) Pathway  
 
The IRE1 exists in the mammalian genome in two isoforms, IREα (it has been the subject 
of more studies) and IREβ (71).  
Engagement of ‘alarm stress pathways’ by UPR sensors may modulate ER stress 
adaptation, apoptosis or physiological outputs that are not directly related to protein-folding 
stress. For example, activation of IRE1α can activate alarm genes by recruiting the adaptor 
protein TNFR-associated factor 2 (TRAF2). This results in the activation of the apoptosis signal-
regulating kinase 1 (ASK1; also known as MAP3K5) pathway and its downstream target JNK (71). 
JNK regulates and activates apoptotic pathways and can also contribute to necrosis in response 
to ER stressors. The JNK branch of the IRE1 pathway can promote cell death.  
It is still not known whether the function of the IRE1 pathway in vivo is generally pro-
death or pro-survival. The RNAse activity of IRE1 can take a role in RNA degradation to reduce 
protein synthesis, a process known as regulated IRE1-dependent mRNA decay (RIDD). Among 
these, the transcription factor X-box-binding protein 1 (XBP1) is particularly important for cell 
survival. The mRNA of XBP1 is synthesized as a nonspliced, untranslated form (uXBP1). When 
IRE1 is activated it removes a small intron resulting in the formation of spliced XBP1 (sXBP1). 
This splicing is commonly used as a readout of UPR activation. sXBP1 is a marker and a key 
regulator of the UPR, as it transcriptionally activates a several genes responsible for restoring ER 
folding capacity (57). Studies reported Huntington’s disease as a neurodegenerative disease 
involving the accumulation of large-protein inclusions generated by mutant huntingtin protein 
leading to upregulation of XBP1s in the striatum of patients (72). 
    19 
 
c) The Activating Transcription Factor 6 (ATF6) Pathway  
 
ATF6 is a basic Leucine zipper (bZIP) transcription factor in its cytosolic domain and 
bounds to the ER membrane in unstressed cells.  ATF6 has two isoforms, ATF6α and ATF6β. Both 
are ubiquitously expressed. It is activated by its release from coat protein (COII) complex, which 
allows it to translocate to the Golgi system. There, it is cleaved by local proteases (S1 and S2 
proteases) releasing the active fragments into the cytoplasm from where it is transported to the 
nucleus. In the nucleus, the active fragments of ATF6f bind specific sequences in promoter 
regions, ER stress response elements in target genes. A key target of ATF6f is the x-box binding 
protein-1 (XBP-1) (44). In addition, during tumour growth, several ER stress activators (hypoxia 
and low glucose) induce resistance to chemotherapy by processes that are suggestive of ER-
dependent mechanisms (73). More significantly, a downstream transcriptional target of ATF6α 
 Binding immunoglobulin Protein (BiP), was described to serve as a malignancy marker for cells. 
Upon induction of ER stress, ATF6α rapidly induces BiP expression, which binds to unfolded 
protein and misfolded protein to improve ER stress. In normal conditions, BiP is localized in ER 
lumen, but upon overexpression, in many types of human cancer, it becomes detectable on the 
cell surface (73,74). Its expression, not only correlates with cancer, cell proliferation and 
histological grade but also correlates with therapies and prognosis response (75). 
Figure 8: The three processes involved in activation of the UPR response. The three main sensors of the 
UPR are PERK, IRE1 and ATF6. Adapted from: (76). 
    20 
 
1.3.3 Ubiquitin Proteassome Pathway (UPP) 
 
In 2004, Avram Hershko, Aaron Ciechanover and Irwin Rose received the Novel Prize in 
Chemistry for the discovery and characterization of the ATP-dependent, ubiquitin-mediated 
protein degradation pathway, unraveling the central role of the Ubiquitin proteasome pathway 
(UPP)  in biology (77).   
Ubiquitin is a highly conserved 76-amino acid protein that can be covalently linked to 
many cellular proteins by the ubiquitination process. Ubiquitylation (also known as 
ubiquitination) is a process carried out by three classes of enzymes: "ubiquitin activating 
enzyme" (E1); "ubiquitin-conjugating enzyme" (E2) and "ubiquitin ligase" (E3). The E1 forms a 
thio-ester bond with ubiquitin; this reaction allows subsequent binding of ubiquitin to E2, 
followed by the formation of an isopeptide bond between the carboxy-terminus of ubiquitin and 
the ε-amino group of a lysine residue on the substrate protein. The latter reaction requires the 
E3 which can only modify a subset of substrate proteins, thereby providing substrate specificity 
to the system. Ubiquitinated proteins are then targeted to the 26S proteasome for degradation 
or experience changes in protein location or activity (78). Deubiquitinating enzymes (DUBs) 
reverse the process of ubiquitination by removing ubiquitin from its substrate protein. DUB 
activity sustains ubiquitin recycling and ensures that ubiquitin molecules remain steady. DUBs 
are categorized into 5 subfamilies: USP, UCH, OTU, MJD, and JAMM, with a specific tissue and 
substrate, each (79). 
The UPP is a process involving two steps: first, the marking of the substrate protein is 
made by the covalent attachment of multiple ubiquitin molecules  Conjugation; and second, 
these proteins are then transported to the 26S proteasome, composed by the catalytic 20S core 
and the 19S regulator, where they are degraded  Degradation. This classical function of 
ubiquitin is associated with housekeeping functions, regulation of protein turnover and 
antigenic‑peptide generation (80).  
The 26S proteasome is a highly abundant complex that serves as the proteolytic arm of 
the ubiquitin-proteasome system. It is composed by two sub-complexes, the 19S regulatory 
particle (RP)  that includes a base and a lid  and the 20S catalytic core particle (CP), forming 
an empty cylindrical structure. The base is formed by six proteins with ATPase activity (Rpt1- 
Rpt6), and four proteins lacking ATPase activity (Rpn1, 2, 10, 13). 
Its functions are to unfold the substrate and allow the access of the unfolded substrate 
into the catalytic chamber.  
The lid is mainly involved in specific recognition of the ubiquitin signal. In addition to the 
19S cap, other proteins and complexes bind to the end of the 20S cylinder and activate it by 
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facilitating the opening of the gate.  The 20S catalytic subunit consists of seven different protein 
subunits. Two rings of subunits denominated alfa (α1 -7) located at the ends of the cylindrical 
structure. The other two rings of subunits called beta (β1-7) are located in the central area (79) 
(81).   
More recently, it has become evident that protein modification by ubiquitin also has 
unconventional functions (non-degradative) such as the regulation of DNA repair and 
endocytosis. These functions are determined by the number of ubiquitin units attached to 
proteins (mono versus poly-ubiquitination) and also by the type of ubiquitin chain linkage (82). 
Several cellular processes are regulated by ubiquitin-mediated proteolysis, such as 
elimination of misfolded or damaged proteins, apoptosis, biogenesis of organelles, cell cycle and 
division, DNA transcription and repair, differentiation and development, immune response and 
inflammation, neural and muscular degeneration, morphogenesis of neural networks, 
modulation of cell surface receptors, ion channels and the secretory pathway, response to stress 
and extracellular modulators, ribosome biogenesis, viral infection and so one (83). All major 
human chronic neurodegenerative diseases, such as Parkinson Disease (PD), AD, Huntington 
Disease (HD) and ALS, are characterized by ubiquitinated proteins that are accumulated in 
abnormal intraneuronal inclusions in the respective affected areas of the Central Nervous 
System (CNS) (84).  
1.3.4 Autophagy  
 
Autophagy is a dynamic and continuous process that degrades cytoplasmic contents, 
misfolded proteins, and excess or damaged organelles, essential for survival, differentiation, 
development and homeostasis. This self-eating process, involves the appropriation of 
cytoplasmic components by a small portion of the membrane, creating an autophagosome. So 
they are fused to the lysosomes, creating an autolysosome, resulting in degradation of cellular 
components via lysosomal enzymes (85). Furthermore, autophagy has been described as being 
generally activated by conditions of nutrient deprivation or invading organisms but has also 
been associated with physiological and pathological processes, as well, such as 
neurodegeneration, stress, heart disease, obesity, and cancer (86).  
Mammalian autophagy is a process that involves several components, such as the 
autophagy-related 1 (Atg1)/unc-51-like kinase (ULK) complex;  two transmembrane proteins, 
Atg9 and vacuole membrane protein 1 (VMP1); proteins that lead to fusion between 
autophagosomes and lysosomes (87); Beclin 1 and other components in the class III 
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phosphatidylinositol 3-kinase complex (PtdIns3K); and finally, two ubiquitin-like proteins 
conjugation systems (Atg12 and Atg8/LC3) (88).  
Three different types of autophagy co-exist in most types of mammalian cells, according 
to the molecular components involved (86):  
Macroautophagy involves the appropriation of cytosolic regions by a de novo formed 
membrane that covers into double-membrane vesicles (autophagosomes) for delivery to 
lysosomes through vesicular fusion, required for the content degradation. Induction of 
macroautophagy leads to the mobilization of a protein kinase type III complex  the initiation 
complex  towards the autophagosome formation. Lipid phosphorylation of this kinase complex 
is essential for the mobilization, in these regions, of the components of two conjugation 
cascades that mediate formation and elongation of the autophagosome membrane. The major 
negative regulator of macroautophagy  the mTOR protein kinase complex  is also there (89); 
Microautophagy, the cytosolic content, is internalized for degradation in single-
membrane vesicles that are made by invaginations in the surface of lysosomes or late 
endosomes. The molecular components that play a role in this autophagic process in mammals 
remain unknown (90);  
Chaperone-mediated autophagy (CMA) differs from the other autophagic pathways on 
the fact that substrates – only soluble cytosolic proteins – are selectively targeted to the 
lysosomal membrane by a cytosolic chaperone and they require unfolding before reaching the 
lysosomal lumen. Internalization of substrate proteins by this pathway is attained by the 
coordinated function of chaperones at both sides of the lysosomal membrane and a membrane 
protein  the lysosome-associated membrane protein type 2A or LAMP-2A  that act both as 
receptor and as an essential component of the translocation complex (90). 
These types of autophagy differ in the mechanisms that mediate the delivery of content 
to lysosomes. They regulate the subset of genes and proteins that act as effectors and 
modulators, in each of them (88).  On the other hand, loss of this mechanism leads to alteration 
in protein quality control, disruption metabolic homoeostasis, and inefficient stress response, 
with a negative impact on mammalian homeostasis (91).  
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1.4 Aggregation reporter systems  
 
A HSP27-GFP reporter system was developed to monitor general protein aggregation in 
HeLa cells by our group. To construct this, human HSP27 promotor and coding region were 
cloned from HeLa cells and fused with Green Fluorescent Protein (GFP). A HeLa stable cell line 
expressing this reporter was generated after transfection of the plasmid containing the HSP27-
GFP fusion and selection by geneticin (G418). GFP was used to monitor the HSP27 expression.  
In a normal situation, cells expressing the HSP27-GFP sensor exhibit a general and homogenous 
green fluorescence, as HSP27 is ubiquitously expressed even in unstressed cells. In situations 
where misfolded proteins are present, the GFP fluorescence is re-localized to foci, 
corresponding to the recruitment of HSP27 to help in the refolding of those proteins, as 
explained above. Thus, the cellular re-localization of this aggregation reporter fluorescence to 
foci can identify situations where protein misfolding is occurring. 
Having a stable cell line expressing this reporter is essential to perform genetic 
screenings to identify genes involved in proteostasis. Genetic screenings are based on the small 
interfering RNA (siRNA) technology. 
siRNAs are small non coding RNA molecules that block translation by binding to 
complementary sites on mRNAs. The siRNAs are generated from double stranded RNA (dsRNA) 
precursors by cleavage of RNase-III-type enzyme termed Dicer. This enzyme can cleave long 
dsRNA into 21-28 nucleotide siRNA double-stranded.  In this process, more efficiently, the 5´end 
of antisense strand of the siRNA becomes a part of a multiprotein complex named RNA-induced 
silencing complex (RISC)  (92,93). The RISC identifies the target mRNAs by complementary base-
pairing, and cleaves it at a specific site. After degradation of mRNA, the expression of 
corresponding protein is reduced (92). In mammalian cells, upon transfection of gene-specific 
siRNA, particular messages are destroyed resulting in a decrease of the corresponding protein 
level. This knockdown facilitates functional analysis of a gene product in the equivalent cells 
(94). This is why siRNAs are a powerful research tool when evaluating many proteins expression, 
dissection the function of independent genes and potential for therapeutic applications (95).  
After a literature review, most of the current reporters described for misfolding protein 
detection are specific for a particular protein (96–99). The recently development, the 
ProteoStat Aggresome Detection Kit is indicated to detect aggregated proteins inside 
aggresomes and inclusion bodies, as storage depots for cargo awaiting degradation by the 
autophagy system (96). Another developed sensor using split-luciferase complementation assay 
only allows the monitoring of Aβ oligomers characteristic of Alzheimer’s disease (98). Also, a 
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Luciferase-based protein aggregate reporter was developed to assess specifically polyQ 
aggregates, a common pathologic feature in neurodegenerative diseases (99). Considering the 
improved interest in detection and quantification of protein aggregation in mammalian cells, 
the development of alternative and more general molecular folding reporters is needed.  
Indeed, our HSP27-GFP reporter is unique in assessing general protein aggregation and 
offers advantages over other mentioned reporters. Using an endogenous source, HSP27 is a 
small heat shock protein family (sHSPs) that binds to any unfolded proteins until the refolding 
action by ATP-dependent heat shock proteins. Furthermore, this molecular chaperone is over-
expressed in stressful situations, and have anti-apoptotic and anti-oxidant functions, particularly 
in pathological conditions (100–102). 
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1.5 Motivation and aims of the study 
Protein conformational diseases have been the subject of several studies performed 
within the past 20 years and have generated important, and partly addressed here, pieces of 
knowledge, while a number of questions still remain unanswered. Although the mechanisms 
associated with the unfolded protein response have been extensively explored, it is crucial to 
identify which genes contribute to protein aggregation. The growing number of tRNA-modifying 
enzymes implicated in a large number of diseases, in particular in conformational disorders, 
suggests that these molecules play important roles in proteostasis. There is a lack of 
experimental demonstration that proves the association between tRNA modifying enzymes, 
protein aggregation and the underlying mechanisms that lead to the onset of disease. We 
hypothesize that deregulation of tRNA-modifying enzymes, in particular the ones that affect 
translation fidelity, results in protein aggregation and activation of UPR, which are characteristic 
of conformational disorders. In order to test this hypothesis, we implemented a fluorescent 
method based on small interfere RNA (siRNA) screening, aiming to identify the human tRNA 
modifying enzymes responsible for homeostasis of the proteome.  
To monitor protein aggregation, we used an immortalized cell line  HeLa cells  stably 
expressing the reporter system HSP27-GFP previously developed by the members of the 
laboratory. In this thesis, it is demonstrated that the stable cell line expressing the protein 
aggregation reporter can be used to monitor situations where misfolding proteins accumulate 
in cells. Also, a fluorescent siRNA based screening of particular tRNA modifying enzymes, 
namely, Elongator complex protein 3 (ELP3) and Alkylated DNA repair protein alkB homolog 8 
(ALKBH8) was performed. ELP3 was identified as an enzyme involved in protein aggregation and 
additional experiments demonstrated that deregulation of this enzyme leads to alterations at 
the level of protein synthesis and increased ubiquitination, showing that this enzyme is essential 
for proteostasis. Taken together, the data collected in this thesis demonstrates that the initial 
hypothesis was correct and additional experiments are now undergoing to identify others 
enzymes involved in proteostasis and to further dissect the molecular consequences of ELP3 
deregulation.  
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CHAPTER 2.  
Materials and methods  
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2.1.1. Cell culture  
 
A stable HeLa cell line, expressing the fluorescent reporter HSP27-GFP, was cultured in 
Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 10% of Fetal Bovine Serum 
(FBS) and 1% of Pen-Strep-Glut (a mixture of the antibiotics penicillin and streptomycin, and the 
amino acid glutamine). These cells were maintained in culture, in an incubator at 37 °C with 5% 
CO2 and 95% of humidity. For all assays, except fluorescence and proteostat, cells were detached 
from the plates with TrypLE Express (ThermoFisher Scientific), a trypsin alternative, and 
incubated 5 minutes at 37 °C. Next, the resultant cell suspension was centrifuged for 3 minutes, 
at 3000 rpm, at Room Temperature (RT). Then, the supernatant was discarded and the pellet 
was ressuspended in fresh medium.  2µL of suspended cells were diluted in 18 µL of trypan blue 
followed by cell counting in a Neubauer chamber. Additionally, the experiments with MG132 
(carbobenzoxy-Leu-Leu-leucinal were performed after incubating cells with 5µM of MG132 for 
18 hours.  
2.1.2. Total protein extraction and quantification 
 
To obtain total protein extracts, pellets were ressuspended in 100 µL of Empigen Lysis 
Buffer (ELB  Annexes). Protein extracts were then sonicated for 2 cycles, at a 60% frequency, 
during 15 seconds each, and centrifuged 20 minutes at 200g at 4 °C. In the end, supernatants 
were kept for the next phase of total protein quantification. During all procedures, cells 
remained on ice to avoid the activity of proteases. Quantification of total protein was performed 
using Pierce™ Bovine Serum Albumin (BCA) Protein Assay Kit (Thermo Scientific), following the 
manufacturer´s instructions. The total extracts were incubated with the BCA reagent for 30 
minutes at 37 °C, followed by absorbance measurement at 575 nm in a microplate reader. 
2.1.3. Insoluble protein fraction 
 
To isolate the insoluble protein fraction, the volume corresponding to 200µg of total 
protein was diluted in ELB to reach a final volume of 100µL. Samples were centrifuged in a micro-
centrifuge (16,000g, 20 minutes) at 4 °C to obtain the insoluble fraction. The resulting pellet was 
solubilized in 80 µL of ELB and 20 µL of NP40 (10%). Samples were sonicated for 20 seconds 
(three times).  After sonication cycles, samples undergone another centrifugation (16,000 g, 20 
minutes at 4 °C). The supernatant was removed, the pellet was washed with 50µL of ELB and 
sonicated for 10 seconds (0,5 cycles with frequency at 50-60%). Finally, a loading buffer was 
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added (10µL of 6x SDS), and samples were denatured at 95 °C during 5 minutes. For SDS-PAGE, 
30µL of sample were added in each well in the acrylamide gel (10%). 
2.1.4. SDS-PAGE and Western Blot 
 
To perform Western Blot analysis, proteins were allowed to migrate through Sodium 
Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE). A concentration in a range of 
10-20 µg of total protein was loaded in the polyacrylamide gel (10%), according to the quantity 
measured in the BCA Protein Assay Kit. Samples were prepared with 6x concentrated protein 
loading buffer and then denatured at 95 °C for 5 minutes. The gel was loaded with a molecular 
marker (Nzy Colour Protein Marker II) in the first well followed by the samples, and then, 1x 
concentrated Running Buffer was added to the electrophoretic container to immerse the 
running gel. SDS-PAGE ran for 2 hours, first at 80 V for 15 minutes to allow the samples to pass 
through the stacking gel, and then at 110 V (Annexes - solutions). Next, proteins were electro 
transferred onto a nitrocellulose membrane in the Trans-Blot® Turbo™ Transfer System for 7 
minutes. The membrane was blocked in 5 or 2% Bovine Serum Albumin (BSA) [diluted in tris-
saline buffer with tween 20 (TBS-T)] and incubated with the primary antibody for 2 hours (Table 
3). The blots were then washed three times for 5 minutes each with TBS-T and then incubated 
with the respective secondary antibody (Table 3) for 1 hour at RT, protected from light. 
Membranes were washed twice with TBS-T for 5 minutes and once with 1x TBS for 5 minutes. 
The membranes were digitalized in the Odyssey scanner and analyzed in its software (LI-COR, 
Biosciences, US). This system is equipped with two infrared channels for direct fluorescence 
detection on membranes (700 and 800 nm, anti-rabbit and anti-mouse respectively). 
Table 3: Antibodies used for Western Blot analysis. 
Primary Antibody Host Secondary Antibody  (1:10 000) 
Anti-Hsp27 (1:1000) 
StressMarq Biosciences 
Mouse Anti-Mouse IRDye®800CW LI-COR 
Anti-BiP (1:1000) StressMarq 
Biosciences 
Rabbit Anti-Rabbit IRDye®680LT LI-COR 
Anti-Ubiquitin (1:1000) Sigma Mouse Anti-Mouse IRDye®800CW LI-COR 
Anti-ATF6 (α) (1:400) 
Stressgen 
Mouse Anti-Mouse IRDye®800CW LI-COR 
Anti-eif2α (1:1000) Cell 
signaling 
Rabbit Anti-Rabbit IRDye®680LT LI-COR 
Anti-eif2α-P (1:4000) Abcam Rabbit Anti-Rabbit IRDye®680LT LI-COR 
Anti-GADPH (1:1000) Abcam Rabbit Anti-Rabbit IRDye®680LT LI-COR 
Anti-β-tubulin (1:1000) 
Invitrogen 
Mouse Anti-Mouse IRDye®800CW LI-COR 
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2.1.5. Reverse transfection with siRNA 
 
siGenome SMARTpool human siRNA targeting different tRNA modifying enzymes were 
obtained from Dharmacon (Thermo Scientific) and reverse transfected into the stable HSP27-
GFP HeLa cell line in 24 well plates (Table 4). Briefly, 12 µL of 500 nM siRNA duplex in 88µL of 
Opti-MEM were added to each well, followed by addition of 1µL/well of the mix of lipofectamine 
RNAi max. After an incubation for 30 minutes 2x104 cells were added to each well in complete 
growth medium without antibiotics. Finally, the cells were incubated for 48 or 72 hours at 37 °C 
in a CO2 incubator.  
 
Table 4: tRNA modifying enzymes tested (based in table 10- Annexes). 
 
 
 
 
Human tRNA modifying enzyme Modification 
  
IKBKAP mcm5U34, mcm5s2U34, ncm5U34, ncm5Um34 
Elp2 mcm5U34, mcm5s2U34, ncm5U34, ncm5Um34 
ELP3 mcm5U34, mcm5s2U34, ncm5U34, ncm5Um34 
Elp4 mcm5U34, mcm5s2U34, ncm5U34, ncm5Um34 
Elp5 mcm5U34, mcm5s2U34, ncm5U34, ncm5Um34 
Elp6 mcm5U34, mcm5s2U34, ncm5U34, ncm5Um34 
KTI12 mcm5U34, mcm5s2U34, ncm5U34, ncm5Um34 
URM1 mcm5s2U34 
CTU2 mcm5s2U34 
CTU1 mcm5s2U34 
TRMU Ϯm5U34,  Ϯm5s2U34 
NSUN2  m5C34, m5C40, m5C48, m5C49 
ALKBH8 (TRM9) mcm5U34, mcm5s2U34 
FTSJ1 Cm32, Cm34, Gm34, ncm5Um34 
Qtrt1 Q34 
TRDMT1 m5C34 
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2.1.6. Immunocytochemistry - Proteostat 
 
Cells were plated on coverslips and treated with negative and positive controls and 
incubated with Proteostat Aggresome Dectetion kit (Enzo Life Sciences International), according 
with the manufacturer’s instructions. Briefly, cells were washed three times with phosphate 
buffered saline (PBS) and fixed with a 4% of paraformaldehyde solution (PFA) for 30 minutes at 
RT. After that, the coverslips were washed three times with PBS and cells were incubated with 
a Permeabilizing Solution (100mL PBS + 1mL glycine (1M) + 5% FBS + 0.1% Triton) for 30 minutes. 
The cells were washed three times with PBS, before and after, an incubated (in darkness) with 
the Dual Detection Reagent, for 30 minutes at RT. Finally, the coverslips were mounted on 
microscope slides using mounting medium and were observed under a fluorescence or a 
confocal microscope. The resulted images were analysed via ImageJ. 
 
2.1.6.1. Mitotracker Red CM-H2XROS 
 
A working solution of 200 nM in cell medium was obtained from 1 mM Mitotracker stock 
solution prepared in dimethylsufoxide (DMSO). Mitotracker staining solution was added to the 
cells after changing the growth medium by Mitotracker working solution. After an incubation of 
30 minutes, cells were washed with fresh medium and fixed in 4% of PFA for 15 minutes. Finally, 
the cells were rinsed 3 times in PBS and coverslips mounted and observed in a Zeiss 
epifluorescence microscope. 
 
2.1.7. Confocal and fluorescence microscopy  
 
Cells were plated in 24 well plates containing coated coverslips (Corning) at a 2x104 
cells/mL cellular density and transfected as detailed in 2.1.5 or treated as detailed in 2.1. All cells 
were then fixed with a solution containing 4% of PFA and incubated for 15 minutes at RT. Some 
coverslips were treated with PROTESOSTAT as detailed in 2.1.6 or incubated with DAPI for 15 
minutes at RT. Coverslips were washed 3 times with PBS and mounted on a glass slide with 
Vectashield mounting medium. Slides were dried in the dark and then observed in the Olympus 
IX-81 confocal microscope, for confocal microscopy experiments or in the Zeiss Axioimager for 
fluorescence microscopy.  
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2.1.8. Cellular viability assay  
 
To determine cell viability the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide), metabolic activity assay was used. Hela HSP27-GFP control and 
transfected cells (1×104cells/well) were cultured in a 96-well plate at 37 °C. The supernatant of 
each well was removed and washed twice with PBS, 12,5 µl of MTT solution (5 mg/mL in PBS) 
and 100µl of medium were then added. After an incubation of 2 hours, the resultant formazan 
crystals were dissolved in dimethyl sulfoxide (100µl) and the absorbance intensity was measured 
by a microplate reader (Bio-RAD) at 575 nm. Cells treated with medium only worked as a 
negative control group. Positive and negative siRNAs controls were used. All experiments were 
performed in triplicated, and the relative cell viability (%) was expressed as a percentage 
relatively to the untreated control cells. 
 
2.1.9. RNA extraction  
 
The RNA was extracted using the NZY Total RNA Isolation kit and the manufacturer’s 
protocol was followed. Briefly, before starting the RNA isolation, a Digestion Mix with DNase I 
and a digestion buffer were prepared. Next, a buffer NR and β-mercaptoethanol was added to 
the cells’ pellet and vortexed vigorously. These solutions were applied to an NZYSpin 
Homogenization column placed in a 2mL collection tube, followed by centrifugation (11000g, 1 
minute), in which the flow-through was saved. The lysate was pipetted and loaded in an NZYSpin 
Binding column and, centrifuged (11000g, 1 minute). The flow-through was discarded and the 
column placed into a new collection tube. The Buffer NI was added, the samples centrifuged and 
the flow-through was discarded and placed in the column back into the collection tube. In this 
moment, the Digestion Mix was applied and incubated at RT for 15 minutes. The Buffer NWR1 
and NWR2 were added, respectively, centrifuged and the flow-through was discarded and the 
column was placed in a new collection tube. 30μL of RNase-free water was added directly in the 
column membrane and centrifuged (11000g, 1 minute) to elute the RNA. RNA was stored at -20  
°C for short-term or at -70 °C for long-term and quantified in a Denovix spectrophotometer.  
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2.1.10. cDNA synthesis 
 
cDNA was synthesized from total RNA using the High Capacity cDNA Reverse 
Transcription kits (Applied Biosystems), according to manufacturer´s instructions. Briefly, three 
major steps were followed in order to synthesize single-stranded cDNA:  
i. 2x Reverse Transcription master mix was prepared, as described in the table 5, 
using the kit components. 
ii. Addition of 10µl of total RNA (100 ng/µL) to the previous master mix (step I) in 
order to create a 1x mix.  
iii. The settings applied in the thermal cycler for the reverse transcription were: 
step 1: 25 °C for 10 minutes; step 2: 37 °C for 2 hours; step 3:  85 °C for 5 minutes 
and 10 °C. 
 
Table 5: Reverse Transcription master mix preparation. 
Components Volume/Reaction (µL) 
10x RT Buffer  2,0 
25x dNTP mix (100mM) 0,8 
10x RT Random Primers 2,0 
MultiScribe Reverse Transcriptase 1,0 
Nuclease- free water 4,2 
Total per Reaction 10 
 
 
2.1.11. Real-Time Polymerase Chain Reaction (RT-PCR)  
 
Expressions of the ELP3, ALKBH8 and GADPH genes were analyzed by Real-Time 
Polymerase Chain Reaction (RT-PCR), using specific TaqMan probes obtained from Thermo 
Fisher Scientific and the components described in table 6. The thermal cycle profile of the qPCR 
machine was set-up as shown in table 7 and the experience was performed in an ABI Prism 7500 
Real-Time PCR System (Applied Biosystems), containing a 96 well block.  
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Table 6: Real time PCR reaction mix. 
Components Volume/Reaction (µL) 
20x  TaqMan® Gene Expression Assay 1 
2x TaqMan® Gene Expression Master Mix 10 
cDNA (100ng/ µL)  4 
RNase- free water 5 
Total volume/well 20 
 
Table 7: Thermocycler programmer (40x)  Standard Conditions. 
Fases Temperature Duration 
Initial denaturation 50°C 2’ 
Denaturation 95°C 10’ 
Annealing 95°C 15’’ 
Extention 60°C 1’ 
Final Extention 4°C ∞ 
 
2.1.12. SUnSET method 
 
To estimate protein synthesis rate, the SUnSET method was used. This technique 
required the incubation of cells with 5 µL of puromycin (10 µL/mL) for 15 minutes. Next, the 
cells were fixed for 15 minutes with PFA 4% and washed twice with PBS and centrifuged (3000 
g, 3 minutes at 4 °C). Cells were ressuspended in 200 µL of cytometric fluid and 10 µL were 
removed from each sample and mixed in a tube as a baseline. The tube´s content was placed 
into the plates or Eppendorf’s tubes to be centrifuged and washed once. Cells were incubated 
with an anti-puromycin antibody (dilution of 1:1000) for 1 hour at RT protected from light. Next, 
50 µL of cytometry buffer was added followed by centrifugation and the supernatant was 
removed. 200μl of cytometry buffer was added and another cycle of centrifugation was 
performed. Two wash steps with 300 µL PBS were followed. Cells were analyzed with a flow FITC 
cytometer detector using the FL1-A (puromycin) and FL4-A (GFP) channels.  
2.1.13. Statistical analysis 
 
Statistical analysis were performed in the GraphPad Prim® v5.01 software, using 
Student´s t-test (paired t test), except for the results of RT-PCR that were assessed by unpaired 
t test. The results were presented as means values of the number of experiments. 
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3.1.1. Evaluation and optimization of the HeLa HSP27-GFP stable cell line  
 
In order to monitor protein aggregation in vivo a HeLa stable cell line expressing the 
HSP27-GFP chimeric reporter protein was generated in our laboratory. The validation of the 
HSP27-GFP reporter has been previously confirmed by transient transfections prior to the 
beginning of this thesis and the stable cell line was established before as well. The work 
developed in this thesis begun by testing the efficiency of the HSP27-GFP sensor expressed in 
the stable cell line. For that, HeLa cells and HeLa HSP27-GFP cells were plated in 6 multi well 
plates at a 2x105 cells/mL density and the reporter expression in the stable cell line was 
confirmed by western blotting, as shown in figure 9.   
 
 
 
 
 
 
 
 
 
As expected, in control HeLa cells (not expressing the reporter), HSP27 was detected as 
a band of ~27KDa, as this chaperone is ubiquitously expressed even in non-stressful situations 
whereas in the stable cell line expressing the HSP27-GFP fusion, a band of ~27KDa is detected 
together with a bigger band, of ~54KDa, that corresponds to the expected size of the fusion of 
HSP27-GFP (both HSP27 and GFP are 27 kDa) (Figure 9). Western blots for GFP were also 
performed. In this case, HeLa cells not expressing the reporter did not express GFP (no band was 
detected), whereas in the stable cell line a band of ~54KDa was observed, as expected. No free 
GFP was detected as cells did not express free GFP (data not shown). 
 In order to test its efficiency, these stable cell lines were incubated with MG132, a 
proteasome inhibitor commonly used as a positive control to test for protein aggregate 
accumulation. As the proteasome is inhibited, cells cannot degrade the potential erroneous 
proteins that are synthesized and as a consequence they accumulate in cells. As expected, after 
incubation with MG132 re-localization of GFP fluorescence to foci was observed in the stable 
HeLa and HeLa HSP27-GFP 
(anti-mouse)  
Band size 
(kDa) 
HeLa 
54 
 
 
27 
 
HSP27-GFP 
HSP27 
HeLa 
HSP27-GFP  
Figure 9:  Stable cell line expressing HSP27-GFP fusion sensor. HSP27-GFP system was transfected in HeLa 
cells using lipofectamine 2000. Stable clones were selected by G418 and expanded. 
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cell line, when compared with the control condition where HeLa HSP27-GFP cells were grown in 
complete medium, displaying a homogeneous GFP expression and no aggregation (Figure 10).  
To further verify that the sensor was working as expected in the stable cell line, we also 
tested the PROTEOSTAT® Aggresome Detection kit that has been used in detection of denatured 
and/or misfolded protein aggregates and inclusion bodies. This kit co-localized with most GFP 
fluorescence foci, indicating that protein aggregation was occurring and the HSP27-GFP sensor 
expressed by the stable cell line was functional. Based on this data, we proceeded for the siRNA 
screening of tRNA modifying enzymes using this stable cell line. 
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Figure 10: Reporter validation: HeLa HSP27-GFP stable cells were kept in complete medium (Ctrl) or incubated with MG132 for 18 hours to inhibit the proteasome. 
After incubation cells were washed, fixed and incubated with proteostat, a protein aggregation commercial detection kit. Control cells display a homogeneous HSP27-
GFP expression and no aggregation. MG132 exposed cells display re-localization of GFP fluorescence to foci that co-localize with proteostat fluorescence, indicating 
that protein aggregation is occurring and HSP27-GFP reporter is functional. Hoescht (blue), GFP (green) and Proteostat kit (red). Confocal fluorescence microscopy, 
magnification 63x. 
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As there was a strong re-localization of fluorescence to foci after incubation of the stable 
cell line with MG132, indicating that there was an accumulation of misfolded proteins in cells 
where the proteasome was inhibited, we decided to further test if there was an increase in 
insoluble proteins in cells after treatment with this compound. After isolating the detergent-
insoluble protein fraction, we found an accumulation of particular insoluble proteins, indicated 
by black arrow, in cells exposed to MG132 and not in control cells, corroborating the 
fluorescence data (Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ctrl 
Total Insoluble 
Ctrl MG132 MG132 
Figure 11: Isolation of insoluble protein fraction: coomassie blue stained SDS- PAGE (10% of 
acrylamide) of total protein fraction and insoluble (hydrophobic) proteins. In insoluble fraction an 
extra band was observed (arrow) in cells treated with MG132. 
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Furthermore, the treatment with MG132 led to an increase in the expression of HSP27, 
as well as in the expression of, HSP27-GFP, as shown by western blot (Figure 12). 
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Figure 12: Stable cell line expressing HSP27-GFP fusion selection.  A) Reporter fusion and HSP27 
expressions were confirmed by western blotting, after incubation with MG132, a proteasome inhibitor. 
There was a significant increase in both the expression of endogenous HSP27 and the HSP27-GFP fusion 
in cells incubated with MG132 when compared to the control. B) Graphic of the % of expression of HSP27 
in HeLa cells with HSP27-GFP reporter.  Statistically significant changes were observed between the 
control and the cells treated with MG132; C) Graphic of the % of expression the HSP27-GFP reporter; 
statistically significant changes in HSP27-GFP expression were observed between MG132 treated cells 
and the control cells. (Data analysis was done using Student's paired t-test, P < 0.05 (*) (N = 3)). 
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3.1.2. Gene-silencing of ELP3, ALKBH8 and GADPH in HeLa cells  
 
We started our tRNA modifying enzyme fluorescent based siRNA screen testing a limited 
number of siRNAs (siGenome SMARTpool human) targeting tRNA modifying enzymes, namely 
ELP3 and ALKBH8. Reverse transfections were optimized by transfecting the mentioned siRNAs 
and siRNA controls. These controls included: a positive control, a validated siRNA that targets 
an abundantly expressed housekeeping (in our case we used GADPH), to measure the efficiency 
of siRNA uptake into cells; a negative control, a siRNA that does not target any gene in the cells, 
to distinguish sequence-specific silencing from non-specific affects; mock, cells only transfected 
with lipofectamine RNAiMax and untreated cells, to determine baseline phenotype, target gene 
level, and cell viability.  Cytotoxicity and silencing efficiency were tested by MTT and RT-PCR, 
respectively (Figures 13 and Figure 14).  
The MTT assay showed a slight decrease in viability of mock and control cells (less than 
20 %), which indicates that both the transfection agent (lipofectamine RNAiMax) and the control 
siRNA are non-toxic.  The positive control, as expected, had a significant effect on cell viability 
(~80 % decrease in viability), indicating that the siRNA transfection method was working. We 
also observed a decrease in the cell viability as an effect of silencing the ELP3 (~34 %), and 
ALKBH8 (~29 %) enzymes.  
MTT Assay: 48h post-transfection
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Figure 13: MTT assay, 48 hours after transient transfection of siRNA in the HeLa HSP27-GFP stable cell 
line. The MTT reduction is measured as absorbance at 575 nm.  A significant decrease in the viability of 
cells was observed for positive control. The viability of mock and control cells has an acceptable decrease 
(less than 20 %).  After siELP3 and siALKBH8 transfection we observed a not statistically significant 
decrease in the viability of cells. Counts from the experiments performed in triplicate from each group 
were compared for statistical significance with Student's t test. P < .001 was considered highly significant 
(***) (N = 3). 
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Figure 14: Validation of gene silencing (siRNA) effect performed by Taqman real-time RT-PCR. 
After ELP3 and ALKBH8 silencing we visualize a downregulation in mRNA levels of these genes 
and no differences in the other conditions at independently experiments. Standard deviations 
were also calculated, based on the Ct standard deviation of the three technical replicates and 
converted to fold change. Unpaired-t test was used. P < .001 was considered highly significant 
(***), and P < .05 (**) was considered significant (N = 3). 
The efficiency of gene silencing is measured by the percentage of target mRNA reduction 
in siRNA-transfected cells relative to control-transfected cells. The average transcript levels from 
four independent siRNA transfection experiments are shown in the figure 14. The cells 
transfected with the siRNA for ELP3 and ALKBH8 showed clearly a significant downregulation in 
mRNA expression for which condition.  
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i. tRNA modifying enzyme fluorescent based siRNA screen  
 
After validating the transfection conditions, fluorescence microscopy analysis of 
transfected cells with the siCTRL, siELP3 and siALKBH8 were performed to identify if any of the 
tested enzymes interfered with proteostasis. Our results indicated that Knockdown of ELP3 led 
to the re-localization of HSP27-GFP to foci (arrows) when compared with the control condition, 
and in formation of only discrete green foci (arrows) after knockdown of ALKBH8 (Figure 15).  
 
A recent finding describes ALKBH8 as a central regulators of cellular oxidative stress 
responses in mammalian systems.  Using a new gene targeted knockout mouse cell system 
researchers have shown that ALKBH8-/- embryonic fibroblasts (MEFs) display elevated Reactive 
Oxygen Species (ROS) levels, increased DNA and lipid damage  hallmarks of cellular stress (104).  
Furthermore, treatment of those cells with various DNA damaging agents led to a pronounced 
increased sensitivity of ALKBH8-/- MEFs, relative to wild type, to H2O2 and Rotenone  which are 
both known to increase intracellular ROS, with Rotenone being an endogenous ROS inducer 
through its ability to perturb mitochondrial function (104). Knowing this, we investigated 
Figure 15: Fluorescent images of HeLa HSP27-GFP cell line after transfection with a siCTRL, siELP3 and 
siALKBH8; cell nuclei (blue). The presence of fluorescent foci are clearly visible and indicated by arrows after 
ELP3 knockdown, when compared to the control condition. Silencing of ALKBH8 led to accumulation of 
discrete fluorescent foci and only in a minority of the transfected cells. Images obtained by Zeiss Axio 
Imager Z1 automated microscope, magnification 60x. 
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phenotype alterations in mitochondria’s, in cells transfected with siALKBH8 and siELP3, using 
the MitoTracker® Red CM-H2XRos Kit. 
 In control cells, mitochondria are uniformly distributed throughout the cytoplasm 
showing the typical elongated shape.  After ELP3 knockdown no significant alterations in 
mitochondrial arquitecture was found. However, after the treatment with siALKBH8, 
mitochondria are fragmented, forming packed masses in the cytoplasm (Figure 16), which are 
typical features of apoptosis (103,104).  
 
Insoluble proteins were observed 72 hours after reverse transfection with the siRNAs. 
Total protein was extracted and quantified with subsequent extraction of the insoluble fraction 
which was run by SDS-PAGE and observed on the Odyssey IR scanner. An increase in insoluble 
protein fraction in ELP3 knockdown cells was observed, which was in accordance with the 
accumulation of fluorescent foci observed by fluorescent microscopy (Figure 17).  
Figure 16: Morphological features of mitochondria: a) control cells b) cells treated with siALKBH8 and 
c) Cells treated with siELP3. Note in a), c) the presence of elongated mitochondria’s and in case b) its 
fragmentation (with spherically-shaped  mitospheres), which were previously linked to a decrease in 
mitochondrial activity and may result in cellular apoptosis. 
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Since there was an accumulation of insoluble proteins after ELP3 knockdown, we 
decided to analyze protein synthesis rate, as there are evidences in conformational disorders 
showing that increased protein aggregation is accompanied by alterations in protein synthesis 
(105). For that we used the Surface Sensing of Translation (SUnSET) method (106). It is based on 
the incorporation of puromycin, an analog of aminoacyl tRNAs, into nascent polypeptide chains, 
inhibiting its elongation. The nascent polypeptide can be detected with fluorescence-activated 
cell sorting (FACS) (Figure 18). Thus, puromycin incorporation directly infers about in vitro 
translation rate.   Our preliminary data indicate that there was a decrease in puromycin 
incorporation in ELP3 knockdown cells, which is an indicator of a decreased protein synthesis 
rate. On the other hand, silencing of ALKBH8 led to a slight increase in puromycin incorporation 
which may indicate an increased protein synthesis rate, but further replicates are needed. 
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Figure 17: Analysis of the insoluble fraction of transfected cells. A) SDS-PAGE of total and insoluble protein 
fractions for each transfection condition. The insoluble profile of cells transfected with siELP3 is more 
pronounced than the other profiles, indicating an accumulation of insoluble proteins. B) Relative amount 
of insoluble fraction protein in transfected cells compared with the control condition (siControl). An 
increase in insoluble fraction in siELP3 knockdown cells is observed, but not in siALKBH8 knockdown cells. 
(Data analysis was done using Student's t-test (N = 3)).   
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Figure 18: Fluorescence microscopy experiments were complemented with the SUnSET method to 
evaluate if protein synthesis rate was affected by knockdown of tRNA modifying enzymes. A) Translation 
analysis using puromycin-labeled proteins. B) The present graph was performed by the values obtained in 
the red channel of incorporated puromycin. (Still, additional replicates are needed) (N = 2)). This 
puromycin-based technology allow to monitor translation by FACs in individual or cell populations for 
siELP3 and siALKBH8 (Fluorescence was detected in the green (FL1- GFP, 510–540 nm) and red (FL4- 
puromycin, 660–690 nm) channels). 
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ii. Proteotoxic stress and quality control pathways analysis  
 
Proteotoxic stress and quality control pathways alterations were evaluated in this study 
by assessing, specific components of the, UPR and UPP systems through Western blotting.  
 
Unfolded Protein Response (UPR) 
 
BiP is a major endoplasmic reticulum (ER) chaperone protein target of the ER stress 
response, or UPR, and an essential regulator of the UPR pathway. During ER stress, BiP 
dissociates from the three transducers (IRE1, PERK, and ATF6), effectively activating their 
respective UPR pathways. By Western Blot we performed the detection and quantification of 
BiP protein expression.  The results obtained indicated a significantly decreased in BiP expression 
after knockdown of ALKBH8 comparison to the control (Figure 19).  
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Figure 19: Analysis of BiP expression.  A) The respective bands of western blot; B) Graphic of the percentage 
of the BiP factor in HeLa HSP27-GFP cells; no statistically significant changes were observed in siELP3 
knockdown cells; statistically significant changes were observed in siALKBH8 knockdown cells, where BiP 
expression was downregulated; (Data analysis was done using Student's t-test; p < .001 was considered 
highly significant (***) (N = 7)). 
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When the cell is experiencing proteotoxic stress, the ATF6 factor is cleaved. The 
resultant fraction induces the transcription of chaperones and enzymes responsible for protein 
folding by helping the cell surviving to proteotoxicity. An expression of ATF6 cleaved increases, 
moderately, in siELP3 when compared to siControl transfected cells (Figure 20). 
 
 
 
 
 
 
 
 
 
 
The eIF2α is a translation initiation factor which, when phosphorylated, inhibits protein 
synthesis. The expression of eIF2α-P factor did not change in any of the tested condition relative 
to the control (Figure 21). 
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Figure 20: Analysis of ATF6 factor expression. A) The respective western blot bands are depicted; B) 
Graphic of percentage of the ATF6 factor cleaved in HeLa cells with Hsp27-GFP reporter. No statistically 
significant changes were observed relative to the control; (Data analysis was done using Student's t-
test (N = 4)). 
Figure 21: Analysis of eIF2α and eIF2α-P expression.  A) The respective western blot bands, eif2α, 
eif2α-P and the endogenous control - β-tubulin are depicted; B) Graphic of % of ratio between eif2α-
P and eif2α-Total, in HeLa HSP27-GFP cells.  No statistically significant changes were observed relative 
to the control; (Data analysis was done using Student's t-test (N = 6)). 
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Ubiquitin-Proteasome Pathway Activation (UPP) 
 
Ubiquitin is a protein that recognizes misfolding proteins and binds to them for 
proteasome degradation. Before substrate degradation the ubiquitin molecules are released 
and recycled. The anti-ubiquitin antibody labels several ubiquitinated proteins in the total 
extract profile. After quantification and normalization, we observed an increase in siELP3 
ubiquitination relative to the control (Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
Ongoing work: After we performed all the reported experiments and established the best 
conditions to perform the siRNA screen, we expanded our screening and started to test the 
implication in proteostasis of other tRNA modifying enzymes. Thus, we obtained the fluorescent 
microscopy images for the elongator complex members (ELP1-ELP6) (Figures 23) and for other 
tRNA modifying enzymes that catalyze modifications at the position 34, such as, CTU1, IKBKAP, 
NSUN2, FSTJ1 and QTRT1. Not all the tRNA modifying enzymes studied lead to re-localization of 
our reporter (Figure 24). However, additional experiments need to be performed to draw a final 
conclusion concerning which of these enzymes are involved in protein aggregate accumulation.  
Ubiquitin 
GADPH siControl siELP3 siALKBH8
0
50
100
150
%
 E
xp
re
ss
io
n
 o
f 
U
b
iq
u
it
in
A)                                                                        B) 
Figure 22: Analysis of protein ubiquitination. A) The respective western blot bands are depicted; B) 
Graphic of the percentage of ubiquitin expression in HeLa HSP27-GFP cells.  No statistically significant 
changes were observed concerning to the control and the siELP3 condition and concerning to the control 
and the condition of siALKBH8, however, cells transfected with siELP3 have higher amounts of ubiquitin 
than the other conditions; (Data analysis was done using Student's t-test (N = 3)). 
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sIKBKAP siCTU1 siQTRT1 siNSUN2 
Figure 23: Fluorescent images of HeLa HSP27-GFP cell line after transfection with si(ELP2-ELP6 without 
ELP3). The presence of fluorescent foci are indicated by arrows. Images obtained by Zeiss Axio Imager Z1 
automated microscope, magnification 60x. Green – GFP, Blue – Hoescht, n=1. 
Figure 24: Evaluation of protein aggregation by fluorescence microscopy after knockdown of some tRNA 
modifying enzymes at position 34.  Not all tRNA modifying enzymes lead to re-localization of HSP27-GFP 
to foci (arrows) when compared with the control. Further experiments are ongoing. Images obtained by 
Zeiss Axio Imager Z1 automated microscope, magnification 60x. Green – GFP, Blue – Hoescht, n=1. 
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4.1. Evaluation and optimization of the HSP27-GFP sensor expressed in the 
stable cell line  
 
HSP27 plays important roles in cells. This chaperone is involved in protein folding, 
oxidative stress reduction, suppression of apoptosis pathways and regulation of cytoskeletal 
actin in cancer, neurodegenerative and cardiovascular diseases (107,108). HSP27 is 
constitutively expressed in most human cells, but its expression levels increase in many types of 
cancer cells making HSP27 an attractive therapeutic target (109). As expected, in the fluorescent 
images we observed that unstressed cells displayed a homogeneous HSP27-GFP expression and 
no aggregation (Figure 10).  
To evaluate the efficiency of our sensor, we used incubated cells with MG132, a peptide 
aldehyde inhibitor of the proteolytic activity of the 26S proteasome complex. It has been 
reported that proteasome inhibitors block the degradation of abnormal proteins, leading to 
their accumulation and activation of the UPR response and synthesis of heat shock proteins, in 
particular HSP27 (110,111). Our western blotting results confirm an increase in HSP27 
expression, after treatment with MG132 (Figure 12), that was accompanied by an increased 
expression of the HSP27-GFP fusion and a re-localization of GFP fluorescence to foci, observed 
by fluorescence microscopy indicating that protein misfolding was increased and HSP27 was 
being recruited to refold those proteins (Figure 10).   
An alternative approach to understand the contribution of the UPP machinery in 
detection of aggregated proteins inside aggresomes and inclusion bodies has been explored by 
ProteoStat Aggresome Detection Kit (96). To evaluate the functionality of our reporter we 
verified the fluorescence co-localization with this commercial kit. The preliminary results 
indicated that our reporter is capable of detecting not only misfolding proteins but also 
aggregated proteins (Figure 10).  In addition, we observed an accumulation of particular 
insoluble proteins in the insoluble fraction of cells exposed to MG132 and not in control cells, 
corroborating the fluorescence data (Figure 11).  
Taken together, these results validated our stable cell line expressing the sensor as 
adequate to identify, by fluorescence microscopy, situations where protein misfolding is 
occurring. Thus, this stable cell line expressing the fusion sensor HSP27-GFP is a good candidate 
to perform siRNA fluorescence based screens to identify genes that are associated with protein 
aggregation. This reporter offers advantages over other protein-aggregation reporters as it is 
able to detect general protein aggregation, while others can only detect aggregation of a specific 
type of protein (98,99,112). For example,  a recently developed reporter to monitor protein 
aggregation uses a split Gaussia luciferase reporter fused to Aβ40/42 that allows the 
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monitorization of Aβ oligomer formation, a key process in Alzheimer´s pathogenesis (98). A 
luciferase-based protein aggregate reporter allows assessing the poly(Q) aggregation found in 
Huntington disease. This reporter directly assesses protein aggregation by means of luciferase 
activity loss (99).  Finally, the first report that directly correlates the average cellular fluorescence 
intensity to the extent of misfolding/aggregation of a target protein, in mammalian cells, was 
reported to use GFP as a folding reporter fused to the C-terminus of a panel of human 
copper/zinc SOD1 mutants. The major aim of this method is to understand the aggregation 
process of SOD1 variants and the identification of their inhibitors (112). Since our fluorescent 
sensor is based on the recruitment of HSP27 to misfolded proteins, it is able to recognize any 
protein misfolding situation that implies HSP27 recruitment, and consequently it is not restricted 
to the identification of a particular protein family.  
 
4.2. ELP3 knockdown affects proteostasis 
 
 
Several studies indicate that post-transcriptional nucleoside modifications of tRNAs at 
the anticodon wobble U34 are highly conserved (12,113,114) . We analyzed some enzymes that 
catalyze chemical modifications at the above-mentioned position, including the ELP3 and 
ALKBH8 enzymes.  More specifically, how the knockdown of these modifications affects 
proteostasis. The results obtained by MTT and RT-PCR assays indicated a successful knockdown 
of both enzymes with the respective siRNAs, with low levels of cytotoxicity of the transfection 
agent and an efficient silencing of both ELP3 and ALKBH8 (Figures 13 and Figure 14).  
Previous studies have shown that knockdown of ELP3 in zebrafish embryos resulted in 
dose-dependent motor axonal abnormalities which is, in fact, a determinant factor in ALS 
disorder (35). ALS is a neurodegenerative disease characterized by axonal retraction that results 
in denervation of the lower motor neurons, muscle dysfunction and consequent atrophy (115). 
The majority of ALS cases are considered to be protein misfolding disorders as the mutations 
found in specific genes (specially, missense mutations in SOD1 gene (chromosome 21)), cause 
the accumulation of misfolded proteins and their aggregation in the cell bodies and axons (115). 
Current findings indicate that these aggregates or, more likely, their oligomeric complex 
precursors, disturbe normal protein homeostasis and induce cellular stress (116). Moreover, 
evidences show that allelic variants of ELP3 are associated with ALS in humans. Indeed, a post-
mortem study correlates the low levels of ELP3 expression in ALS individuals’ brains with a 
genotype variation of this gene.  Also, a genetic screen in Drosophila identified two different loss 
of function mutations, both in ELP3 in neuronal communication  synaptic defects  and survival 
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– aberrant axonal outgrowth (35). As ELP3 knockdown led to accumulation of protein 
aggregates, as shown in this thesis, and, as it is known, this enzyme is involved in ALS 
development, it is reasonable to speculate that lack of ELP3 activity in ALS is correlated with the 
proteostasis impairments characteristic of this disease. Our results clearly show that knockdown 
of ELP3 and other Elongator components induces the re-localization of HSP27-GFP to foci when 
compared with the control (Figure 15). As the reporter used detects protein aggregation, we can 
assume that when re-localization of green foci occurs, misfolding proteins are increased, which 
is in accordance with the findings by other group regarding the proteostasis impairment in the 
absence of ELP3 or U34 modifications.  In yeast, a functional Elongator complex is crucial for the 
translation of stress-related genes. Yeast lacking ELP3, for example, had an impaired response 
to stress conditions as they cannot translate specific stress-induced mRNAs as efficiently as the 
wild type cells that have the required modification that allows a more efficient codon 
recognition (117). Also, a recent study shows that lack of U34 both in S. cerevisiae and C. elegans 
leads to translation inefficiency and proteotoxic stress (26).  Although this study did not focus 
on ELP3, it shows the impact of the lack of modifications in position 34 in proteostasis. As ELP3 
is involved in such modifications, this study indicates that defects in this enzyme (or others in 
particular the ones belonging to the Elongator complex) may lead to proteostasis impairments 
due to ribosome pausing, for example. Furthermore, it was demonstrated that deletion of ELP3 
in cortical stem cells triggers ER stress and the activation of UPR response and autophagy by 
decreasing codon translation rates (118). Through the SUnSET method we confirmed a decrease 
in protein synthesis rate after ELP3 knockdown (Figure 18), but further replicas are needed to 
draw definitive conclusions. Additionally, results illustrated in figure 17 confirmed that an 
increase in the insoluble protein fraction also causes alterations in protein expression profiles. 
Evidences also showed that increased protein aggregation is accompanied by alterations in 
protein synthesis (105). 
Aggregates found in ALS patients, as well as mouse models, contain ubiquitin, a protein 
required to target proteins via the proteasome degradation pathway (119). The 
misaccumulation of ubiquitinated misfolded proteins might badly affect the proteasome 
machinery and, consequently, impair normal proteasome degradation. Our results indicated a 
slight increase in ubiquitinated proteins in ELP3 knockdowns, indicating that the proteasome 
was probably being affected by the absence of this enzyme (Figure 22) in detriment of non-
activation of UPR response (Figure 19, Figure 20 and Figure 21).  If the load of misfolded proteins 
accumulated in cells, due to ELP3 absence, exceeds the cell ability to cope with them, we expect 
that the proteasome is negatively affected and its activity is decreased. The hypothesis that 
aberrations in the ubiquitin/proteasome system may contribute to human disorders 
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characterized by accumulation of misfolded proteins has been supported (116,120,121). These 
studies indicate that the continued expression of mutant SOD1 leads to proteasome inhibition 
and motor neuronal death, which in part explains the pathogenesis of mutant SOD1-linked ALS 
(121). Also, a transient expression of aggregated poly(Q) proteins cause inhibition of the UPP 
(120,122). These findings postulate that protein aggregates can inhibit the UPP by saturating the 
capacity of one or more molecular chaperones required for UPP function or by direct interaction 
with the proteasome catalytic subunits (123,124), which is in accordance with our data. 
As mentioned, we performed a preliminary screening including other tRNA modifying 
enzymes. Knockdown of most of the ones belonging to the Elongator Complex resulted in 
accumulation of misfolded proteins in the cell cytoplasm (Figure 23). As previously mentioned, 
several studies associated some ELP3 variants with ALS, strongly suggesting that the Elongator-
dependent pathways may be deregulated in distinct neurological disorders (101). Evidences 
showed that the subunit 4 depletion results in the brain-specific downregulation of genes 
implicated in cell motility and migration, whereas a study identified ELP5 and ELP6 as key players 
for migration, invasion and tumorigenicity of melanoma cells, as integral subunits of Elongator 
(102, 103). Taken together, this data points out for a relevant role of different elongator complex 
members in different cellular mechanisms indicating that deregulation of these enzymes will 
have an impact in the cell’s function. However, additional experiments are needed to 
unequivocally conclude the relevance of those enzymes for proteostasis and whether their 
mechanism is similar to ELP3, or not.  
 
4.3.  ALKBH8 knockdown does not induce protein misfolding but affects 
mitochondria  
 
We only found discrete green foci in cells, when ALKBH8 was silenced (Figure 15), 
indicating that knockdown of this enzyme was not affecting proteostasis in a significant manner. 
However, ALKBH8 -/- mice display an extensive mismodification of wobble uridines that reduced 
the fidelity and efficiency of protein translation by recoding of the UGA stop codon to 
Selenocysteine (Sec) (125).  
Recent evidences showed that knockdown of ALKBH8 enzyme induces apoptosis in 
bladder cancer cells via downregulating the protein expression of survivin (126). We also 
observed an increase in cell death after ALKBH8 knockdown, but we still need to perform 
additional experiments to verify if apoptosis is, in fact, increasing in the absence of ALKBH8. In 
addition, survivin is also reported in tumorigenesis through the interaction with caspase 3 and 
7 and inhibition of Bax and Fas induced apoptosis (127,128). These studies pointed to a possible 
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correlation between apoptosis activation and an alteration in mitochondrial morphology and, in 
fact we observed that after this enzyme knockdown, mitochondria were severely affected and 
most of them were fragmented forming packed masses in the cytoplasm (Figure 16).  
Notably, we found that BiP was downregulated upon ALKBH8 knockdown (Figure 19), 
but this phenomenon was not accompanied by deregulation of other UPR-related proteins. 
Nevertheless, a study indicates that higher levels of BiP would delay or prevent UPR, whereas 
lower levels could cause a premature or prolonged UPR (129). Further studies are required to 
understand the role of ALKBH8. 
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4.4. Conclusions and future work  
 
 
The knowledge on the roles that tRNA modifying enzymes play in human diseases is 
opening a whole new and exciting field for research and for development of novel therapeutics. 
The vast majority of the published research on tRNA modifications has been carried out in 
bacteria, in lower eukaryotes and, to less extent, in mammalian cell lines.   
Our major goal was the implementation of a tRNA modifying enzyme fluorescent based 
siRNA screen using a stable cell line expressing a protein aggregation reporter system  HSP27-
GFP. The evaluation of our reporter indicated that it can be a good candidate in siRNA 
fluorescence based screens to identify genes associated with protein aggregation. Fluorescence 
microscopy experiments revealed that Knockdown of ELP3 resulted in re-localization of HSP27-
GFP to foci. This situation was less evident after ALKBH8 silencing. The mitochondrial 
morphology was also evaluated. We found more fragmented mitochondrias in the cytoplasm of 
siALKBH8 cells, indicating a possible dysfunction.  In the case of siELP3, the fluorescent data were 
complemented with an increase of the insoluble protein fraction and a decrease in protein 
synthesis rate. The activation of UPR and UPP were also studied by western blotting, but further 
replicates are needed to draw definitive conclusions on the activation of the UPR. All findings 
indicated that downregulation of ELP3 affects protein folding and proteostasis and, in case of 
ALKBH8, some protein misfolding may be occurring, but is possible that the main consequence 
of ALKBH8 downregulation is apoptosis induction. Additional screening of others tRNA 
modifying enzymes that catalyze modifications at the position 34 are ongoing. 
The results obtained expanded our knowledge about the biological function of tRNA 
modifying enzymes, in particular its impact in proteostasis. In a near future, the presence of 
apoptotic cell populations will be analyzed by flow cytometry, through Annexin V, and the 
proteins in the insoluble protein fraction of ELP3 knockdown cells will be identified by mass 
spectrometry.  To identify genes and other signaling pathways that may be deregulated due to 
absence of tRNA modifying enzymes, we will perform gene expression microarrays. We also 
intend to study the effects of upregulation in some tRNA modifying enzymes. 
This research contributed to the establishment of a stable cell line expressing a protein 
aggregation fluorescent sensor that can be used to perform genetic screenings as well as 
screenings of chemical compounds. Moreover, by using this stable cell line expressing the 
developed fluorescent sensor, we were able to identify ELP3 as a relevant enzyme for 
proteostasis and further studies are ongoing to validate this molecule as a novel therapeutic 
target for age-related diseases.  
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We believe that in the near future other tRNA modifying enzymes will be identified as 
proteostasis regulators thanks to the implementation of our siRNA screening.  
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 Proteostasis Network 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 25: Proteostasis Network. Misfolded proteins in the cytosol or in cellular compartments, such as ER 
and mitochondria, are recognized by chaperones which support their refolding into the native structure.  If 
misfolded proteins cannot be properly refolded, they are targeted for degradation mainly by the ubiquitin-
proteasome system into small peptides. Aggregated protein are surrounded by the autophagosome and 
degraded after fusion of lysosomes with the autophagosome. Degradation products of the proteasome and 
the autophagy pathway are mainly recycled as amino acids for protein synthesis. Failure to refold or degrade 
misfolded proteins can lead to their accumulation and aggregation that interfere with normal protein 
homoeostasis and resulting in proteotoxic effects. Adapted from: (133).  
Stress response (ROS production; 
mitochondrial dysfunction); 
Gene expression alterations; 
Error propagation in translation; 
Cell degeneration and disease; 
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Table 8: Some human diseases associated with tRNA modifications. Adapted from: (44). 
Abbreviations: mt, mitochondrial; m22G, N2,N2-dimethyl guanosine; m5C, 5-methylcytosine; m7G, 7-
methylguanosine; mcm5s2U, 5-methoxycarbonylmethyl-2- thiouridine; m5U, 5-methyl uridine; m1G, 1-
methylguanosine; mcm5U, 5-methoxycarbonylmethyluridine; ms2t6A, 2-methylthio-N6-threonyl 
carbamoyladenosine; tm5U, 5-taurinomethyluridine; tm 5s2U, 5-taurinomethyl-2-thiouridine; s2U, 2-thiouridine. 
tRNA Modification Related 
Human Diseases 
Modification Gene involved 
Neurological intellectual 
disability  
2´O-methylribose 
m22G 
m5C 
m7G 
A-to-I editing 
FTSJ1b 
TRM1 
NSUN2 
WDR4c 
ADAT3 
Familial dysautonomia  mcm5s2U IKBKAP  
ALS  mcm5s2U ELP3 
Rolandic epilepsy mcm5s2U ELP4 
Dubowitz-like syndrome  m5C NSUN2 
Cardiac Noonan-like syndrome m5C NSUN2 
Respiratory bronchial asthma  mcm5s2U IKBKAP 
Cancer skin, breast, and 
colorectal 
m5C NSUN2 
Breast cancer  wybutosine  TRMT12 
Colorectal cancer  m1G HRG9MTD2e 
Urothelial cancer  mcm5U HABH8 (HALKBH8) 
Breast, bladder, colorectal, 
cervix, testicular cancer  
mcm5U HTRM9L 
Epigenetic cancer  m5C DNMT2 
Metabolic Type 2 diabetes  ms2t6A CDKAL1 
MELAS  τm5U mt-tRNA Leu (UAA) 
MERRF τm5s2U mt-tRNA Lys (UUU) 
Infantile liver failure S2U MTU1 (TRMU) 
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Table 9: tRNA modifying enzymes selection. 
Human tRNA modifying enzyme Modification 
ADAT3 A-to-I editing 
IKBKAP mcm5U34, mcm5s2U34, ncm5U34, ncm5Um34 
Elp2 mcm5U34, mcm5s2U34, ncm5U34, ncm5Um34 
ELP3 mcm5U34, mcm5s2U34, ncm5U34, ncm5Um34 
Elp4 mcm5U34, mcm5s2U34, ncm5U34, ncm5Um34 
Elp5 mcm5U34, mcm5s2U34, ncm5U34, ncm5Um34 
Elp6 mcm5U34, mcm5s2U34, ncm5U34, ncm5Um34 
KTI12 mcm5U34, mcm5s2U34, ncm5U34, ncm5Um34 
TRIT1 (MOD5) A-to-I editing 
URM1 mcm5s2U34 
CTU2 mcm5s2U34 
CTU1 mcm5s2U34 
PUS1 26272834(35)366567 
PUS3 38, 39 
TRMT1 m2,2G26 
TRMT2A m5U54 
TRMT2B m5U54 
NSUN2  m5C34, m5C40, m5C48, m5C49 
ALKBH8 (TRM9) mcm5U34, mcm5s2U34 
TRMT10A m1G9 
TRMT11 m2G10 
TYW1 yW37 
TRMT12 yW37 
LCMT2 yW37 
TRMU tRNA-specific 2-thiouridylase (2-thiolation of 
the wobble base of mt tRNAs) 
TRMT5 m1G37, m1I37, yW37 
FTSJ1 Cm32, Cm34, Gm34, ncm5Um34 
TRMT61A m
1
A 
Qtrt1 Q34 
TRDMT1 m5C34 
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I. Solutions  
 
Protein Lysis Buffer for Western Blot:  
 
ELB (10 mL) 
 Triton X ------------------- 50 µL 
 Hepes pH=7 (1M) -------- 500 µL 
 NaCl (5M) ---------------- 500 µL 
 H2O ------------------------ 8,95 mL 
 
ELB complete (5 mL) 
 ELB ---------------------------------- 4,645 mL 
 *Roche 50x (1 tablet in 2 ml)----- 100 µL 
 DTT (1M) --------------------------- 5 µL 
 Naf (1M) ---------------------------- 5 µL 
 EDTA (0,5 M) ---------------------- 20 µL 
 EGTA (100 µM) ------------------- 50 µL 
 *PMSF (40 µM) ------------------ 125 µL 
 Na3VO4 (100 mM) ---------------- 50 µL 
* Are only added when the use of the ELB! 
 
In addiction:  ELB complete (1 mL) 
 ELB ---------------- 955 µL 
 Roche 50x -------- 20 µL 
 PMSF -------------- 25 µL  
 
 
PBS (1L) 
 
 
 
 
 
 
Reagents Quantities 
NaCl (137 mM) 8,00 g 
KCl (2,7 mM) 0,20 g 
Na2HPO4 (10 mM) 1,44 g 
KH2PO4 (1,8 mM) 0,24 g 
Add H2O to 1 L and adjust pH = 7.4 
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Two Acrylamide gels (10%) 
 
Reagents Resolving (10%) lower Stacking (4%) upper 
ddH2O 3,6 mL 3,464 mL 
Tris-Cl  3,75 mL (pH= 8,8) 1 mL (pH= 6,8) 
Acrylamide*29.1 2,5 mL 0,5 mL 
SDS 10% 100 µL 50 µL 
ADS 10% 100 µL 50 µL 
TEMED** 10 µL 10 µL 
*Acrylamide is a neurotoxin and should be handled with care. ** Added just before pouring gel.  
 
Note: The stacking gel has a low concentration of acrylamide and the running gel a higher concentration capable of 
retarding the movement of the proteins. 
 Running Buffer (10x) for SDS-PAGE 
 
 
 
 
TBS 10x 
 
 
 
 
Trans-Blot Turbo, Transfer Buffer (1x) 
 
 
 
 
 
Reagents Quantities 
Tris  30,2 g 
Glycine  144 g 
SDS 10,0 g 
Dissolve in 1L of H20 
Reagents Quantities 
Tris  30,0 g 
NaCl 80,0 g 
KCl 2,00 g 
Add 1L of H20 and adjust pH = 7.6 
Reagents Volumes 
Tranfer Buffer- 5x 200 mL 
Ethanol (~85 %) 200 mL 
Add 600 mL of H20.  
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Tris-Acetate-EDTA (TAE) Buffer (50x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents Concentration 
Tris  40,0  mM 
EDTA 2,00 mM 
Acetic Acid  20,0 mM 
Adjust pH = 8.5 and dilute in H20 
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 "There will come a time when you believe everything is finished.  
That will be the beginning." 
